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ABSTRACT             
 
 
 
 
Sodium glucose co-transporter 2 inhibitors (SGLT2i) have begun to show promise as an 
add-on to insulin therapy in patients with type 1 diabetes (T1D), however the effects of these 
drugs on plasma glucagon concentrations in T1D are not yet known. We investigated whether 8 
days of SGLT2i treatment altered plasma glucagon concentrations in response to voluntary 
physical activity and insulin-induced hypoglycemia in male and female rats with streptozotocin-
induced T1D. SGLT2 inhibition did not alter basal or post-exercise glucagon concentrations and 
did not affect exercise-associated changes in blood glucose levels. Additionally, SGLT2 
inhibition did not affect voluntary running distance. However, in males, SGLT2 inhibition 
appeared to have suppressed the glucagon response to insulin-induced hypoglycemia 
(+40.4±48.6 pg/mL vs +22.7±30.8 pg/mL, p=0.02) and decreased the time to taken to reach 
hypoglycemia (63.8±17.2 min vs 30±13.4 min, p<0.0001). These results have potentially 
concerning implications for the use of SGLT2i in the treatment of T1D. 
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1. INTRODUCTION          
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new category of drug prescribed 
for the treatment of hyperglycemia in patients living with type 2 diabetes (T2D). These drugs 
are currently undergoing clinical trials examining efficacy and safety for the treatment of type 
1 diabetes (T1D), but have not yet been approved by the United States Food and Drug 
Administration (FDA) or Health Canada for this patient population. Preliminary clinical trials 
have demonstrated the benefits of SGLT2 inhibitors to individuals with T1D as an adjunct to 
insulin therapy with respect to metabolic control (i.e. glucose lowering agent) as well as renal 
and cardiovascular protection through changes in kidney function and blood pressure 1. The 
main metabolic benefits include reductions in hyperglycemia exposure, as measured by 
hemoglobin A1c (HbA1c), as well as reductions in body weight and total daily insulin intake 2. 
Recently, studies have begun to investigate the effects of SGLT2 inhibitors on their potential 
for augmenting glucagon secretion from the alpha cells of the pancreas in healthy and diabetic 
animal models and humans 3–7. Increases in glucagon secretion may make the hypoglycemic 
actions of the drug less effective but may also have protective effects for patients when low 
blood glucose (hypoglycemia) develops during exercise, or with insulin overtreatment. 
Emerging data also suggest that chronic SGLT2 administration in patients living with type 1 
diabetes may increase the risk for euglycemic ketoacidosis, a potentially life threatening 
condition 8. We are not aware of any studies, in humans with type 1 diabetes or in animal models 
of the disease, examining the effects of SGLT2 inhibition on blood glucose counterregulation 
to insulin-induced hypoglycemia or its effects during exercise. This project aimed to evaluate 
the interaction of empagliflozin, a commonly prescribed SGLT2 inhibitor for patients with 
T2D, with insulin-induced hypoglycemia and with exercise in a rat model of type 1 diabetes.   
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1. LITERATURE REVIEW          
1.1. GLUCOSE HOMEOSTASIS 
Glucose homeostasis is regulated by a complex network of various cells, tissues, 
hormones, neurotransmitters, and other biological factors. In healthy individuals, the 
concentration of glucose in the blood is maintained at a range of ~ 4-7mmol/L with slight 
fluctuations occurring outside of this range throughout the day. Concentrations above or 
below normal blood glucose levels, termed hyperglycemia and hypoglycemia respectively, 
can cause both short and long-term consequences to the body. Fluctuations in blood glucose 
concentrations, at their simplest, are a result of changes to the ratio of the glucose rate of 
appearance (Ra) to the glucose rate of disappearance (Rd). These fluctuations are mediated by 
hormonal signals and the uptake and production of glucose by various organs. It has been 
widely established that the endocrine cells of the pancreas, and their hormonal secretions, 
play a dominant role in glucose homeostasis, however there are many other organs and tissues 
that greatly contribute to this regulation including the liver, skeletal muscle, and kidneys. 
 
2.1.1 Organ Contribution to Blood Glucose Regulation 
2.1.1.1 The Endocrine Pancreas 
The endocrine cells of the pancreas are grouped together, forming islands within the 
pancreatic tissue. These islands are referred to as the islets of Langerhans. Five types of cells 
exist within these islets: a-cells, b-cells, d-cells, PP cells and e-cells. Of these cells, the 
insulin-producing b-cells, and the glucagon-producing a-cells are central to the maintenance 
of blood glucose regulation. Insulin is an anabolic hormone that aids in carbohydrate 
metabolism by promoting the uptake, utilization, and storage of glucose molecules in insulin-
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sensitive tissues including the liver, skeletal muscle, and adipose tissue. By doing so, it lowers 
the concentration of glucose present in the blood. When blood glucose levels begin to rise 
above the normal range, often occurring postprandially, insulin is secreted to lower blood 
glucose levels back into the target range. Glucagon, on the other hand, is a catabolic hormone 
that increases blood glucose levels through hepatic glycogenolysis, as well as hepatic and 
renal gluconeogenesis. Glucagon is often released during exercise, sleep, or other periods of 
fasting in order to satisfy the energy requirements of the body and prevent or treat 
hypoglycemia. With their opposing effects, insulin and glucagon work in tandem to tightly 
regulate blood glucose levels and balance the anabolic and catabolic requirements of the 
body.   
The control of insulin and glucagon secretion is complex and has been shown to involve a 
variety of regulatory factors. Pancreatic islets act as functional units that modify insulin and 
glucagon secretions by sensing and responding to changes in blood glucose concentrations. 
Additionally, each pancreatic islet contains a heterogeneous population of cells at close 
proximity to one another, creating an ideal arrangement for paracrine interactions. There has 
been support for interactions between a-cells, b-cells, and the somatostatin-producing d-cells 
in the normal maintenance of blood glucose levels 9, however there is still a lack of 
understanding into the exact relationships and mechanisms involved in these interactions.  
The primary regulator of insulin secretion is glucose, and the mechanism by which 
pancreatic b-cells modify their secretion of insulin by sensing changes in glucose 
concentrations is well known. Glucose molecules freely diffuses into b-cells through glucose 
transporters (GLUTs) where, once metabolized, they trigger a signaling cascade that leads to 
the exocytosis of insulin-containing secretory vesicles 10. Changes in glucose concentration 
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and insulin secretion largely parallel one another, with higher blood glucose concentrations 
leading to a greater amount of insulin secretion 11. Alternatively, even minimal decreases in 
glucose concentrations can lower insulin secretion in healthy humans 12. 
The response of a-cells to changes in glucose concentrations is more complex and there is 
debate over whether this is primarily a direct response to glucose or an indirect response as a 
result of paracrine interactions and various other factors 13–15. Rodent a-cells express GLUT1 
mRNA, which implicates a potential mechanism for direct glucose sensing 16. However, more 
recently, the presence of sodium glucose co-transporters (SGLT) 1 and 2 have been 
discovered in human alpha cells and SGLT2 has been associated with the ability to modulate 
glucagon secretion from these cells 3. On the other hand, the idea that glucagon secretion 
might be under paracrine regulation was originally proposed several decades ago, and has 
since been supported by studies examining the interactions of b-cell secretions, such as 
insulin, γ-aminobutyric acid (GABA), and Zinc (Zn2+), with a-cell function 17–19. 
Given the function of glucagon, it is intuitive to expect an inverse relationship between 
glucose concentrations and glucagon secretion. In line with this notion, hypoglycemia is 
known to induce an increase in glucagon concentrations in humans 20. Additionally, low 
glucose concentrations have been shown to stimulate glucagon secretion in a perfused rat 
pancreas 21. However, there has been some evidence to suggest that this interaction with 
glucose may be dependent on the presence of neighbouring islet cells and a decrease in 
insulin secretion, and that isolated a-cells may in fact interact with glucose in a similar 
fashion as b-cells 22,23. Interestingly, studies have shown that glucagon secretion appears to be 
maximally inhibited around euglycemic glucose concentration (6-7mmol/L) in intact human 
islets, isolated mouse islets, and glucagon-releasing cells from hamsters 24,25. In these same 
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studies, glucose was also shown to paradoxically stimulate glucagon secretion at higher 
concentrations (12-30mmol/L). Moreover, elevated circulating glucagon levels have long 
been associated with poor diabetes control (i.e. chronic hyperglycemia) 26. It has been 
proposed that this observation could be due to a concentration-dependent effect of glucose on 
glucagon secretion, or a result of paracrine interactions with b-cell secretions 25,27, however 
the exact mechanisms behind the glucose-regulated secretion of glucagon is still being 
uncovered.  
In addition to glucose signaling and paracrine interactions of a and b-cell, insulin and 
glucagon secretion also appear to be regulated by somatostatin, produced by the pancreatic d-
cells, which has been shown to exert inhibitory actions on both the a and b-cells 28. Other 
regulatory factors include incretins hormones released from the intestines, amino acids and 
fatty acids, and signals from the hypothalamus via autonomic nerve innervation.  
 
2.1.1.2 The Liver 
A primary target of insulin and glucagon is the liver, which acts at the main site of 
glucose storage in the body and accounts for 75-80% of all endogenous glucose production 29. 
Once insulin and glucagon are secreted, they travel directly to the liver via the portal vein, 
where these hormones can be found in their highest concentrations. The liver maintains a 
balance between the storage of glucose in the form of glycogen, termed glycogenesis, and the 
production of glucose from glycogen and non-carbohydrate sources, termed glycogenolysis 
and gluconeogenesis, respectively 30. Approximately 50 years ago, it was first suggested that 
the relative concentrations of insulin and glucagon may be more significant to glucose 
homeostasis than their individual concentrations 31,32. Later, the insulin:glucagon ratio (IGR) 
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was determined to be the main regulator of endogenous glucose production (EGP) from the 
liver 33. After a meal, the IGR increases to promote the storage of glucose through 
glycogenesis and lipogenesis (the production of fatty acids). During periods of fasting, this 
ratio decreases in order to promote the production of glucose through glycogenolysis and 
gluconeogenesis. The importance of the IGR continues to be recognized in recent research as 
a key mechanism behind changes in blood glucose concentrations. 
 
2.1.1.3 Skeletal Muscle  
Glucose Uptake by Skeletal Muscle at Rest 
 Skeletal muscle is a primary location for glucose uptake. Depending on the 
requirements of the cell, once glucose has been transported across the membrane, it can either 
be oxidized and used for energy production or stored in the form of glycogen. Glucose uptake 
into skeletal muscle is dependent on GLUT4 transporters in the plasma membrane and 
transverse tubules that allow glucose to pass into the cell down its concentration gradient 34. 
However, the majority of GLUT4 is stored intracellularly until a signal is given for membrane 
translocation 35.  
At rest, skeletal muscle is dependent on insulin for glucose uptake. Insulin stimulation 
of insulin receptors (IR) on the cell surface triggers a signaling cascade, inducing the 
translocation of GLUT4 into the membrane. The ability of insulin to elicit this response 
determines the muscle’s sensitivity or resistance to insulin. 
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Exercise and Glucose Homeostasis 
 It is well known that physical activity increases skeletal muscle uptake of glucose. 
Studies have revealed both insulin-dependent and insulin-independent mechanisms behind 
this increase in glucose uptake. Exercise has been shown to increase skeletal muscle blood 
flow in adults 36,37. This increase in blood flow would expectedly result in improved glucose 
and insulin delivery to target tissue. Additionally, studies in rats and humans have 
demonstrated capillary recruitment in response to exercise, increasing the surface area 
available for glucose transport 38,39. A study in dogs, however, suggested that changes in 
blood flow account for less than 30% of the exercise-induced increase in muscular glucose 
uptake 40.  
 The primary mechanism through which exercise increases skeletal muscle glucose 
uptake is currently considered to be via an insulin-independent, contraction-induced 
translocation of  GLUT4. The ability for muscle contraction to induce an uptake of glucose 
without the presence of insulin has been well established 41,42. Support for the requirement of 
GLUT4 in this process comes from a study where electrical stimulation of skeletal muscle in 
GLUT4 knock-out mice resulted in almost a complete loss of contraction-induced glucose 
uptake 34.  
 Exercise has also been shown to increase insulin sensitivity. As little as one session of 
physical activity is enough to elicit an improvement in insulin sensitivity, with this effect 
continuing to last 48 hours post exercise 43. Furthermore, consecutive bouts of exercise have 
been shown to increase the amount of GLUT4 translocation in response to a standard dose of 
insulin, an effect that may be attributed to an increase in muscle GLUT4 content 44,45. 
However, there are additional theories that may explain these adaptations, and the exact 
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mechanisms behind the exercise-induced increase in insulin sensitivity are still being 
investigated. The effects of insulin, muscle contraction, and changes in blood flow are 
additive, and work synergistically to increase glucose uptake into skeletal muscle during 
exercise 46. 
 In order to account for the increased energy requirements during exercise, changes in 
glucoregulatory hormone secretion must occur to ensure a balance between the glucose rate of 
appearance (Ra) and the glucose rate of disappearance (Rd) and prevent hypoglycemia. This 
response can vary depending on both the duration and intensity of exercise. As mentioned 
previously, the IGR is the main driver of changes in EGP and therefore plays an important 
role in glucose homeostasis during physical activity. During prolonged, moderate intensity 
exercise, the IGR decreases in order to stimulate EGP and counteract the increase in glucose 
clearance from the blood 47. A decrease in blood glucose concentrations during exercise can 
cause the release of other glucoregulatory hormones as well, including catecholamines 
(epinephrine and norepinephrine), growth hormone, and cortisol 48. During intense exercise, 
however, catecholamines have been shown to increase 14-18 fold, as opposed to the 2-4 fold 
increase that can be seen during moderate physical activity 49. This response is similar to what 
is seen during periods of acute stress, and causes an increase in EGP and a reduction in 
glucose uptake. In healthy individuals, this response is followed by an increase in insulin 
secretion during recovery to prevent hyperglycemia 50. 
 
2.1.1.4 The Kidneys 
The kidneys are responsible for regulating the amount of glucose excreted from the 
body, and by extension, regulate the amount of glucose reabsorbed into systemic circulation. 
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This is accomplished by sodium glucose co-transporters 1 and 2 (SGLT1 and SGLT2) located 
in the proximal convoluted tubule of the kidney, which allows for the reabsorption of glucose 
from the filtrate back into the blood stream. In a healthy individual, these transporters prevent 
the loss of glucose in the urine by enabling the reabsorption of nearly 100% of all glucose 
entering the kidneys 29. With increasing levels of glucose in the blood, renal glucose 
reabsorption tends to increase until it reaches its threshold at a blood glucose concentration of 
around 10-11mmol/L 51. At blood glucose concentrations above this threshold, glucose begins 
to be excreted into the urine, causing glycosuria. Though less prominent, the kidneys also 
contribute to glucose homeostasis through renal gluconeogenesis 29.  
 
2.1.2  Sex Differences in Glucose Metabolism 
Humans have clear metabolic sex differences, however, these differences must be 
interpreted with caution as they can also be affected by factors such as age, physical fitness, 
nutritional status, and hormonal changes. Sex differences in glucose metabolism can be seen 
through distinctions in insulin sensitivity, and metabolic and hormonal changes during 
exercise and hypoglycemia.  
  
2.1.2.1 Insulin Sensitivity 
 Research relating to sex differences in insulin sensitivity has been somewhat 
inconsistent, however there is a general consensus towards a greater whole body insulin 
sensitivity in females compared to males. Several large studies investigating sex differences 
in impaired fasting glucose and glucose tolerance have suggested that men may be more 
prone to develop insulin resistance than females 52–54. Furthermore, some studies have utilized 
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a hyperinsulinemic-euglycemic clamps to estimate whole-body insulin sensitivity as well as 
skeletal muscle insulin sensitivity by analyzing the rate of glucose infusion per kilograms of 
whole body mass or lean body mass, respectively 55. Insulin sensitivity in skeletal muscle is of 
interest because skeletal muscle is the primary location for insulin-induced glucose uptake 56. 
Though some of these studies failed to show significant differences between sexes, several 
demonstrated a significantly higher estimation of whole body insulin sensitivity 57,58 and 
skeletal muscle insulin sensitivity 59,60 amongst females. For the most part, these results have 
been consistent with rodents studies. Aged male rats have been shown to be more prone to 
insulin resistance induced by a high fat diet 61. Macotela and colleagues then demonstrated an 
increased insulin sensitivity in adipose tissue of female mice compared to male mice 62. 
Furthermore, in 2011, Gorres et al. published a study which demonstrated that estrogen 
receptor stimulation leads to an increase in insulin stimulated skeletal muscle glucose uptake, 
implicating estrogens in the mechanisms behind the increased insulin sensitivity seen in 
female skeletal muscle. In summary, there is some evidence suggesting a greater whole body 
insulin sensitivity in females, possibly due to the actions of estrogens, however the lack of 
consistency in this area of research is likely due to the myriad of factors involved in insulin 
sensitivity.  
 
2.1.2.2. Metabolic and Counterregulatory Responses to Exercise and Hypoglycemia 
 It is well known that women tend to have a higher body fat percentage than men 63. 
Under basal conditions, women tend to store circulating free fatty acids (FFA) while men tend 
to oxidize them 64. However, studies have shown that during moderate intensity endurance 
exercise, women have a lower respiratory exchange ratio (RER), a decreased glucose Ra and 
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Rd, and have greater lipolytic and ketogenic responses than men 65–67. These results suggest 
that females rely more on lipid oxidation and less on carbohydrate stores in comparison to 
males during period of moderate endurance exercise.   
 Research examining sex differences in counterregulatory responses to insulin-induced 
hypoglycemia and exercise suggests that men exhibit a greater counterregulatory response 
than women. Depending on both the degree of hypoglycemia and the time spent in 
hypoglycemia, studies have found sex-linked disparities in counterregulatory responses in 
different hormones including glucagon, epinephrine, norepinephrine, growth hormone, and 
cortisol 68–72. Additionally, one study has shown that men have greater counterregulatory 
responses to moderate exercise than women 73. After 90 minutes of physical activity, 
epinephrine, norepinephrine, and pancreatic polypeptide concentrations were significantly 
increased in men compared to women, while there were no differences in the levels of plasma 
glucagon, cortisol, or growth hormone between sexes.  
 
2.2 TYPE 1 DIABETES 
2.2.1 Pathophysiology and Etiology of Type 1 Diabetes 
Type 1 diabetes (T1D) is an autoimmune disease where the b-cells of the pancreas are 
targeted by the body’s immune system and are consequently destroyed. This destruction leads 
to the inability of the body to produce insulin. Therefore, individuals with T1D must take 
exogenous insulin in order to maintain the blood glucose concentrations necessary for 
survival, which can be done either through injections or with an insulin pump.  
The etiology behind the development of T1D is unclear. Our current understanding is that 
T1D is a multifactorial disease caused by a combination of genetic predisposition as well as 
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environmental factors 74. Over 50 genetic loci have been associated with the development of 
T1D 75. Of these, the strongest association is to the human leukocyte antigen (HLA) gene 
family, a group of genes encoding the proteins of a complex involved in the regulation of the 
human immune system 76. Monozygotic twin studies have identified an over 50% 
concordance rate for the development of T1D, supporting the idea that T1D has a strong 
genetic component but is triggered by an unidentified environmental factor 77. Possible 
environmental factors contributing to the development of this disease include viruses, the 
intestinal microbiome, and dietary factors such as cow’s milk and vitamin D 78.  
Despite insulin treatment, individuals with T1D are still faced with the lifelong challenge 
of blood glucose management. Given the narrow therapeutic range of insulin and the variety 
of physiological processes that contribute to glucose metabolism, it is nearly impossible for 
individuals with T1D to avoid dysglycemia and 75% of adults with T1D fail to reach the 
recommended goal for glycemic control 79. Hyperglycemia and hypoglycemia each lend 
unique challenges to T1D management. 
 
2.2.2 Hyperglycemia and Diabetic Ketoacidosis 
Hyperglycemia is an excess amount of glucose in the bloodstream and is the defining 
characteristic present at the time of diabetes diagnosis. It is generally caused by a lack of 
insulin relative to the requirements of the body. Symptoms of hyperglycemia include nausea, 
thirst, frequent urination, and weight loss. Hyperglycemia can have long-term macrovascular 
and microvascular complications potentially leading to the development of conditions such as 
cardiovascular disease, retinopathy, nephropathy, and neuropathy. In T1D, hyperglycemia 
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may amplify itself through positive feedback involving glucose reabsorption in the kidneys 
and dysregulated glucagon secretion 80–84. 
Hyperglycemia influences, and is influenced by glucose reabsorption in the kidneys. 
As mentioned previously, in healthy individuals, renal glucose reabsorption increases with 
rising blood glucose concentrations until it reaches its threshold at around 10-11mmol/L. In 
patients with both type 1 and type 2 diabetes, the maximal capacity of renal glucose 
reabsorption is increased by ~20% and the threshold for glucose reabsorption has been show 
to increase up to ~14mmol/L 51,85,86. This is likely due to glucose transporters in the proximal 
convoluted tubule, which appear to be increases in patients with T2D 87. The increase in renal 
glucose reabsorption that occurs with increasing blood glucose levels further contributes to 
hyperglycemia in patients with diabetes. At blood glucose concentrations that exceed the 
maximal threshold of glucose reabsorption, glucose is then excreted in the urine causing 
glycosuria. 
Hyperglycemia can lead to diabetic ketoacidosis (DKA), a life-threatening condition 
that involves an abnormally high production of ketone bodies from the liver. The two main 
types of ketone bodies are acetoacetate and b-hydroxybutyrate. Ketone body production 
commonly occurs in healthy individuals during periods of lipid oxidation, however the 
abnormally high levels of ketone bodies seen in DKA cause bodily fluids to become 
dangerously acidic. This abnormally high level of ketone bodies is a result of severe insulin 
deficiency, which promotes ketone production by leading to increased levels of circulation 
FFA and promoting gluconeogenesis in the liver. Ketone production is also known to be 
influenced by high glucagon levels, which may be inappropriately raised during 
hyperglycemia 83,88,89. 
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with an increase in insulin resistance, which promotes hyperglycemia even further 90. In 
individuals with T1D, DKA is often seen at the time of diagnosis, before an insulin regiment 
has been started, but can also occur due to illness, poor compliance with insulin treatment, 
and malfunctioning diabetes care equipment.  
 
2.2.3 Hypoglycemia, Exercise, and Defects in Counterregulation 
Hypoglycemia is defined as a deficiency of glucose in the blood and, according to the 
Diabetes Canada Clinical Practice Guidelines, occurs when blood glucose concentrations fall 
below 4mmol/L 91. Hypoglycemia is a severe, life threatening condition that requires 
immediate medical treatment. Depending on the severity of hypoglycemia, symptoms can 
include trembling, nausea, dizziness, weakness, and seizures, and if left untreated, can lead to 
loss of consciousness and death. For individuals with T1D, hypoglycemia is an unavoidable 
side effect of exogenous insulin intake and tightly regulated blood glucose concentrations. On 
average, individuals with T1D experience two episodes on symptomatic hypoglycemia per 
week and one episode of severe hypoglycemia per year 92. In T1D, hypoglycemia is often 
caused by either an excess amount of insulin or an increase in glucose uptake during physical 
activity. Healthy individuals have physiological mechanisms in place to prevent 
hypoglycemia, however these mechanisms become defective in individuals with T1D. 
The first line of defense against hypoglycemia in a healthy individual is a decrease in 
insulin secretion as blood glucose levels drop into the range of 4.4-4.7mmol/L, followed by a 
response in counterregulatory hormone secretion as blood glucose levels continue to drop 12. 
With exogenous insulin treatment, individuals with T1D are unable to immediately reduce 
circulating levels of insulin to prevent hypoglycemia. Furthermore, research has shown that 
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individuals with T1D lose the ability to adequately respond to hypoglycemia through 
counterregulatory hormones. As blood glucose concentrations continue to fall into the range 
of 3.6-3.9mmol/L, glucagon is normally secreted in order to treat hypoglycemia 20. However, 
in T1D, glucagon response to hypoglycemia quickly becomes blunted, beginning as early as 1 
month after diagnosis and deteriorating with time 93. The mechanism behind this lack of 
glucagon response is still unclear, but may involve defective a-cell glucose sensing, the 
absence of paracrine signalling through b-cell secretions, reduced autonomic stimulation, or 
elevated pancreatic somatostatin levels 94. Without the ability to decrease circulating insulin 
and sufficiently increase glucagon secretion, individuals with T1D rely on a sympathoadrenal 
response and catecholamine secretion. Unfortunately, this response can also become 
defective, as patients with T1D on intensive insulin therapy were shown to have a reduced 
and desensitized epinephrine response to hypoglycemia 95.  
 These defects in counterregulation make physical activity challenging for individuals 
with T1D, and fear of hypoglycemia can prompt some individuals to refrain from exercise. In 
T1D, exercise can have varying effects on blood glucose levels depending on the type and 
duration as well as the circulating levels of insulin in the bloodstream at the time of activity. 
Moderate-intensity aerobic exercise generally promotes a drop in blood glucose levels and 
can often lead to hypoglycemia. As mentioned previously, exercise can also affect insulin 
sensitivity for up to 48 hours post-exercise. A study in children with T1D found that 
moderate-intensity physical activity caused blood glucose levels to decrease during, 
immediately after, and 7-11 hours after exercise 96. This latent decrease in blood glucose 
levels can lead to nocturnal hypoglycemia, a dangerous scenario where hypoglycemia occurs 
during sleep. It is important to note that physical activity can also cause a rise in blood 
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glucose levels if accompanied by an adrenergic response, which often occurs as a result of 
anaerobic activity.  
Strategies for hypoglycemia prevention during exercise mainly include adjusting pre-
exercise insulin intake, to account for the delayed effects of exogenous insulin, and 
carbohydrate supplementation. However, since individuals with T1D still experience frequent 
episodes of hypoglycemia, current strategies aimed at preventing hypoglycemia are clearly 
insufficient. This population could benefit greatly from an additional therapy aimed at 
preventing hypoglycemia. 
 
2.2.4 Rodent Models of Type 1 Diabetes 
 Rodent models of T1D have been an indispensable asset to the progression of T1D 
research. There are several types of rodent models of T1D; chemically induced models, 
spontaneous autoimmune models, genetically induced models and virus-induced models of 
T1D. The most popular of these models are the streptozotocin (STZ)-induced diabetic 
rodents, Bio-Breeding Diabetes-Resistant (BBDR) rats, and nonobese diabetic (NOD) mice.  
 
2.2.4.1 Streptozotocin-induced Diabetes 
STZ is a glucose-resembling compound synthesized by the bacteria Streptomycetes 
archromogenes. Because of its pancreatic b-cell toxicity, STZ is frequently used to produce a 
chemically induced model of T1D in rodents. STZ elicits its toxic effects by entering 
pancreatic b-cells through the Glut-2 transporter, causing DNA damage and the inhibition of 
insulin production. It can be administered to rodents via intraperitoneal (i.p.) or intravenous 
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(i.v.) injection usually as either a single high dose (100-200mg/kg in mice, 35-65mg/kg in 
rats) or in multiple low doses (20-40mg/kg per day).    
STZ-induced diabetes provides a simple, quick, and relatively inexpensive means of 
inducing pancreatic b-cell loss in rodents. It is general thought to be a useful model for 
research involving drug trials that act independently of b-cells. Although STZ-induced 
diabetes can be a useful model of T1D, it does have some disadvantages. STZ may have toxic 
effects to other organs besides the pancreas, including the liver, kidneys, brain, lungs, 
intestines, and testis. Additionally, some studies have suggested that b-cell regeneration may 
be possible in STZ-induced diabetic rodents given insulin treatment, with better glycemic 
control being associated with improved recovery 97,98. These factors must be considered when 
using a STZ-induced model of diabetes.   
 
2.3 SGLT2 INHIBITION 
2.3.1 History of SGLT2 Inhibitors 
SGLT2 inhibitors, also known as gliflozins, are class of drug used to treat patients 
with type 2 diabetes. Their primary function is to induce the excretion of glucose in the urine 
by preventing glucose reabsorption in the kidneys. The use of this class of drug dates as far 
back as the year 1835, when a French chemist discovered phlorizin, a naturally occurring 
SGLT1 and SGLT2 inhibitor, in the bark of an apple tree 99. Approximately 50 years after its 
discovery, phlorizin’s ability to produce glycosuria was realized and its connection to the 
kidneys was elucidated 100. After this realization, phlorizin was administered to humans in 
order to test kidney function, and has even been used in attempts to inhibit tumor growth 
101,102. It was later discovered that phlorizin was effective at normalizing blood sugar levels in 
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a diabetic rat model, however, the poor oral bioavailability and gastrointestinal side effects of 
the compound prevented it from being approved for human use 103. In more recent years, 
these drugs have been modified to improve bioavailability and specificity, so that they can be 
prescribed to patients with T2D. There are now many varieties of SGLT2 inhibitors being 
tested and prescribed all over the world, with 4 variations approved by the US FDA and 
Health Canada for the treatment of T2D (dapagliflozin, canagliflozin, empagliflozin, and 
ertugliflozin). These drugs have not yet been approved for the treatment of T1D, however 
clinical trials are currently underway.  
 
2.3.2 Mechanism of SGLT2 Inhibitor Action 
SGLT2 is a transport protein found in the proximal convoluted tubule of the nephron 
of the kidney that allows for the symport of one glucose molecule along with one sodium 
molecule. SGLT2 functions in the reabsorption of glucose from the filtrate back into systemic 
circulation, and, in healthy individuals, prevents the loss of glucose in the urine. Nearly 100% 
of the glucose that is found in the filtrate is reabsorbed into circulation. SGLT2 accounts for 
approximately 97% of glucose reabsorption in the kidneys, with sodium glucose co-
transporter 1 (SGLT1) accounting for the reabsorption of the other 2-3% of glucose that 
enters the filtrate 104,105. SGLT2 inhibition blocks this reabsorption of glucose, causing 
glycosuria, the excretion of glucose in the urine. Consequently, SGLT2 inhibitors act as an 
effective, insulin-independent, treatment for hyperglycemia. It should be noted that the 
complete inhibition of SGLT2 causes the excretion of only 50-60% of filtered glucose, which 
is likely due to the compensatory role of SGLT1 104,106,107.  
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2.3.3 The Effects of SGLT2 Inhibition in Type 1 and Type 2 Diabetes 
2.3.3.1 Type 2 Diabetes 
 The treatment of T2D with SGLT2 inhibitors has demonstrated significant 
improvements in blood glucose control, specifically in the percentage of glycated hemoglobin 
(HbA1c), an approximate average of blood glucose concentrations over the last 3 months. A 
meta-analysis conducted by Monami et al found a maximum reduction in HbA1c of 0.6% 
after 24 weeks of SGLT2 inhibition in patients with T2D, with this improvement lasting up to 
1 year 108. Furthermore, SGLT2 inhibition has been shown to be effective at improving blood 
glucose levels along with other types of diabetes medication, including metformin, 
sulfonylureas, and insulin 109,110.  
 In addition to improvements in blood glucose levels, SGLT2 inhibition has also been 
shown to reduce body weight in people with T2D, a disease that is often associated with 
increased body weight and obesity. After 52 weeks of dapagliflozin treatment, patients with 
T2D had a persistent placebo-corrected reduction in body weight of over 2kg, with four times 
more patients having a ³5% reduction in body weight than the placebo group 111. SGLT2 
inhibitor treatment has also been associated with reductions in blood pressure, through both 
weight-loss dependent and independent mechanisms. Patients treated with either 100mg or 
300mg of canagliflozin both showed significant reductions in systolic blood pressure in 
comparison to the placebo group, where 58% of these reductions were weight-loss 
independent while the other 42% appeared to be associated with weight-loss 112.  
 Improvements in cardiovascular and renal outcomes have also been attributed to 
SGLT2 inhibitor use. In 2015, a large, multicenter study, called the EMPA-REG OUTCOME 
trial, found a 38% relative risk reduction of cardiovascular related deaths in patients on 
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empagliflozin in comparison to the placebo group 113. The CANVAS program, a trial 
examining the cardiovascular and renal effects of canagliflozin, also showed fewer 
cardiovascular related deaths in the SGLT2 inhibitor treated group compared to the placebo 
group 114. This study did not find any significant differences in renal outcomes, but did see 
possible benefits of canagliflozin with respect to albuminuria, estimated glomerular filtration 
rate, the need for renal-replacement therapy, and death from renal causes. 
  Because SGLT2 inhibitors are a blood glucose lowering drug, one of the initial 
concerns with its use was the possibility for the development of hypoglycemia. While some 
studies have shown a potential increased risk of hypoglycemia with SGLT2 inhibition 109,115, 
these results are likely associated with the use of sulfonylurea or insulin in these patients. The 
majority of studies have shown similar rates of hypoglycemia with and without SGLT2 
inhibitor treatment 110,111,113,116,117. One study even demonstrated a reduced occurrence of 
nocturnal hypoglycemia with SGLT2 inhibitor treatment with the use of a continuous glucose 
monitor 118. The most common side effect associated with SGLT2 inhibition is genital 
infections. Clinical trials have shown an approximate fourfold increase in the incidence of 
genital infection with SGLT2 inhibition 108. Interestingly, SGLT2 inhibition has also been 
associated with the occurrence of euglycemic DKA, where DKA develops without the 
presence of hyperglycemia 119. The mechanism behind this may be similar to the mechanisms 
behind the development of DKA, with an “artificially” lowered blood glucose caused by the 
large increase in renal glucose clearance induced by SGLT2 inhibition.  
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2.3.3.2 Type 1 Diabetes 
 Clinical trials assessing the treatment of type 1 diabetes with SGLT2 inhibitors in 
addition to insulin therapy have shown similar benefits to those seen with T2D. To date, there 
have been three large trials examining the efficacy of SGLT2 inhibitors in T1D. In 2015, 
Henry et al. demonstrated that 18 weeks of treatment with canagliflozin decreased HbA1c, 
body weight, and total daily insulin dosage in individuals with T1D 120. In the DEPICT-1 and 
2 studies, dapagliflozin treated patients also had a significant decrease in HbA1c, body weight 
and total daily insulin dose compared to the placebo treated individuals after 24 weeks 121,122. 
The inTandem3 trial showed that 24 weeks of treatment with sotagliflozin, an SGLT1 and 
SGLT2 inhibitor, caused significantly greater reductions in HbA1c, body weight, insulin 
dose, as well as systolic blood pressure in patients with T1D compared to placebo treated 
patients 123. In earlier studies, treatment with SGLT2 inhibitors has also been shown to reduce 
cardiovascular risk factors and improve kidney function by decreasing hyperfiltration (an 
abnormally high flow rate of filtered fluid through the kidney), blood pressure, body weight, 
and improving plasma lipid profiles in individuals with T1D 124,125. In all of these studies, no 
differences were found in the incidence of hypoglycemia between placebo treated groups and 
SGLT2 inhibitor treated groups, in spite of the fact that glucose levels tend to drop as more 
glucose is passed into the urine. This may indicate some improvement in glucose 
counterregulation to hypoglycemia with SGLT-2 treatment. Potential side effects of SGLT2 
inhibitor use in individuals with T1D include the risk of urinary tract or genital infections, and 
increases in the incidence of DKA 2. This increased risk of DKA may be linked to an increase 
in glucagon secretion and/or reduced renal clearance of ketones 126.  
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2.3.3.3 SGLT2 Inhibition and Glucagon Secretion 
SGLT2 inhibition has recently been associated with changes in glucagon secretion, 
however the mechanisms behind this association are still being uncovered. In 2014, Merovci 
et al., and Ferrannini et al. were the first to show that patients with T2D had an increase in 
plasma glucagon concentrations with SGLT2 inhibitor treatment 4,5. Later, researchers 
discovered the presence of SGLT2 on a-cells obtained from non-diabetic humans 3. In this 
same study, the researchers demonstrated how treatment with the SGLT2 inhibitor 
dapagliflozin increased glucagon secretion in both healthy human islets exposed to glucose 
concentrations at or below 6 mmol/L, as well as in healthy mice. This increase in glucagon 
secretion was hypothesized to be caused by the inhibition of SGLT2 on the a-cells of the 
pancreas. Pedersen et al supported this idea with a study that created a mathematical model of 
glucagon secretion, which predicted SGLT2 to be involved in a-cells glucose sensing 6. 
Additional studies performed in healthy and diabetic mice also showed an increase in 
glucagon secretion with SGLT2 inhibition 127,128. On the other hand, in 2017, Wang et al. 
demonstrated how dapagliflozin did not alter plasma glucagon concentrations, but suppressed 
glucagon signaling and EGP from the liver in rodent models of type 2 diabetes 7. They also 
found a reduction in glucose stimulated glucagon secretion in SGLT2 inhibitor treated 
pancreata extracted from a rat model of type 1 diabetes. Evidently, additional research is 
needed to uncover the true effects of SGLT2 inhibitors on glucagon secretion and action in 
the presence, and absence, of intact islets.   
Because individuals with T2D are already afflicted with abnormally high levels of 
glucagon, the increase in glucagon secretions observed in SGLT2 inhibitor treated patients 
has been viewed as a potential concerning side effect of this drug 129. However, for 
 23 
individuals on exogenous insulin treatment, like patients with T1D, increasing glucagon 
secretion could also have important implications for hypoglycemia prevention. If this effect 
on glucagon secretion holds true for people with T1D as well, it could potentially explain the 
lack of an increased risk of hypoglycemia seen with this glucose-lowering drug, and be an 
additional benefit of SGLT2 inhibition to individuals with T1D. 
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3. RATIONALE AND OBJECTIVES        
 
3.1 RATIONALE 
Insulin treatment alone is not sufficient to prevent dysglycemia in patients with T1D. 
Tightly regulated blood glucose concentrations are crucial for maintaining health and 
preventing long-term complications in these patients, but this tight blood glucose control may 
put individuals at risk of hypoglycemia because of the narrow therapeutic range of insulin or if 
exercise is involved 130. In a healthy individual, an increase in glucagon secretion normally 
occurs as blood glucose concentration begin to fall in order to prevent hypoglycemia 20. 
However, over time, individuals with T1D lose the ability to appropriately respond to 
hypoglycemia with an increased glucagon response 93. Additional strategies are clearly needed 
in order to prevent hypoglycemia in individuals with T1D. An ideal therapy would act to restore 
the normal glucagon response to hypoglycemia.  
SGLT2 inhibitors have proven to be a beneficial adjuvant to insulin therapy. Currently these 
drugs are viewed as strictly a treatment for hyperglycemia, with the potential to improve 
glycemic control and kidney function while reducing insulin intake and cardiovascular risk 
factors in patients with T1D  2,124,125. Clinical trials in individuals with T1D have shown no 
increase in the rate of hypoglycemia with SGLT2 inhibitor use despite the fact that these drugs 
lower blood glucose concentrations by increasing glucose output in the urine. Recently, there 
has been several studies indicating that SGLT2 inhibition increases glucagon secretion, 
specifically in patients and rodent models with T2D as well as in isolated pancreatic islets 3–5. 
The mechanism behind this has been suggested to be a direct action of SGLT2 inhibitors on the 
a-cells of the pancreatic islets 3,6. The in vivo effects of SGLT2 inhibition on glucagon secretion 
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in T1D remains unknown. If these drugs increase glucagon secretion in patients with T1D, they 
may have the potential to restore some level of glucagon response to hypoglycemia that 
frequently occurs with accidental insulin over administration or with exercise in these 
individuals 131.  
This study used a streptozotocin-induced rat model of T1D to test the in vivo effects of 
SGLT2 inhibition on the glucagon response to insulin-induced hypoglycemia and exercise. 
With this approach, we aimed to get a proper understanding of the effects of SGLT2 inhibition 
on glucagon secretion in T1D by measuring glucagon concentration in both the systemic 
circulation and the portal vein, the latter of which is not possible without invasive surgery. 
Additionally, we chose to conduct this experiment in both male and female animals in order to 
account for potential sex differences that may be present regarding response to SGLT2 
inhibition and physical activity. This initial rodent study is key in understanding the potential 
of SGLT2 inhibitors to augment glucagon secretion before it can be translated into similar 
investigations performed in humans with T1D.  
 
3.2 OBJECTIVES 
The primary objective of this study was to determine the effects of SGLT2 inhibition on 
glucagon concentrations and blood glucose concentrations during insulin-induced 
hypoglycemia, as well as in exercise in a rat model of type 1 diabetes. Secondary measurements 
included investigating the effects of SGLT2 inhibitors on voluntary running wheel activity, and 
exploring any sex differences that may be present in these measurements.  
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3.3 HYPOTHESES 
We hypothesized that the SGLT2 inhibition will increase the secretion of glucagon in a 
streptozotocin-induced rat model of T1D. Furthermore, we anticipate that this rise in glucagon 
secretion will reduce the fall in blood glucose concentrations seen during both insulin 
overtreatment and exercise (Figure 1). Because SGLT2 inhibition improves blood glucose 
control, we also expect to see an increase in voluntary running wheel activity in the drug treated 
rats compared to the placebo treated animals due to an alleviation of negative symptoms. We 
do not expect to see any sex differences in regard to glucagon secretion.  
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Figure 1: Glucose homeostasis in individuals with and without type 1 diabetes (T1D) at rest and during exercise.  
A) Glucose homeostasis in a healthy individual at rest. In healthy individuals, blood glucose concentrations are 
maintained at ~5.5mmol/L by maintaining a balance between the rate of glucose appearance (Ra) and disposal (Rd) in the 
bloodstream. The liver and kidneys have the ability contribute to the glucose Ra through endogenous glucose production 
(EGP). The ratio of insulin to glucagon secretion from the pancreas acts as the primary regulator of EGP from the liver. 
The kidneys also contribute to EGP through gluconeogenesis, and also contributes to blood glucose concentrations by 
preventing the loss of glucose in the urine. Glucose is removed from the blood stream and taken up into various tissues 
including skeletal muscle and adipose tissue. B) Glucose homeostasis in a healthy individual during exercise. During 
physical activity, skeletal muscle uptake of glucose increases. To compensate for these increased glucose requirements 
and maintain euglycemia, EGP often rises during exercise. Exercise causes an increase in glucagon (a decrease in the 
insulin to glucagon ratio) to promote EGP and maintain blood glucose levels. C) Glucose homeostasis in an individual 
with T1D treated with both insulin and an SGLT2 inhibitor, at rest. In type 1 diabetes, blood glucose concentrations 
become much more variable. The pancreas no longer produces insulin, and insulin must be taken exogenously through 
multiple daily injections, or with an insulin pump. Additionally, glucagon secretion is dysregulated in T1D. Glucagon  
levels appear to be inappropriately elevated postprandially, and glucagon response to hypoglycemia is suppressed. With 
SGLT2 inhibitors as an add-on therapy to T1D, the kidneys become a main source of glucose disposal by eliminating 
glucose from the blood stream and into the urine. D) Our hypothesized model of glucose homeostasis in an individual 
with T1D treated with both insulin and an SGLT2 inhibitor, during exercise. During physical activity, skeletal 
muscle glucose uptake is increased in T1D as well. Since glucagon secretion is dysregulated in T1D, this increased 
glucose uptake during exercise can often lead to hypoglycemia. We hypothesize that in T1D, SGLT2 inhibiters will act 
on the pancreas to increase glucagon secretion and restore some level of glucagon response to hypoglycemia.  
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Introduction   
Type 1 diabetes (T1D) is a life-threatening disease that involves the constant self-
management of blood glucose concentrations, a task which can often be both challenging and 
demanding. With insulin treatment alone, patients with T1D continue to experience frequent 
dysglycemia and face long-term health complications, including an increased risk of 
cardiovascular and renal disease 132. Hypoglycemia is common in patients with T1D, who 
have been estimated to experience an average of two symptomatic episodes of hypoglycemia 
per week 92. Since hypoglycemia is often induced by either an excess amount of insulin or 
physical activity, fear of hypoglycemia can be a major preventative of tight glycemic control, 
and has been shown to be the main barrier to exercise in people with T1D 133. The frequency 
of hypoglycemia in these patients can be attributed to a combination of the inherent side 
effects of exogenous insulin treatment, and the lack of an appropriate counterregulatory 
response. Specifically, the counterregulatory response of glucagon to hypoglycemia has been 
shown to be blunted in individuals with T1D, deteriorating further with time 93. Reducing the 
intensity of insulin treatment is currently not a feasible means of decreasing hypoglycemia 
occurrence since it would result in hyperglycemia. Patients with T1D would benefit from an 
additional therapy that reduces insulin intake and improves long-term health outcomes, 
making sodium glucose co-transporter 2 (SGLT2) inhibitors an attractive potential add-on to 
insulin treatment in this population 129. 
SGLT2 inhibitors, also known as gliflozins, are a class of drugs that have already been 
established as an effective treatment for hyperglycemia in patients with type 2 diabetes (T2D) 
134. These drugs act on transporters in the kidneys to inhibit the reuptake of glucose from the 
filtrate, thereby inducing glycosuria, the excretion of glucose in the urine 135. Clinical trials 
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are currently being run to examine the safety and efficacy of SGLT2 inhibition in patients 
with T1D, and many studies have already begun to show promise in these individuals 120–125. 
A few larger trials have shown reductions in HbA1c, body weight, and insulin intake for 
SGLT2 inhibitor treated individuals with T1D 120–123. Other smaller studies have also shown 
improvements in both cardiovascular and renal risk factors and plasma lipid profiles for these 
patients 124,125. Because of their glucose excreting effects, one of the initial concerns with 
SGLT2 inhibitor treatment was the potential for the development of hypoglycemia. However, 
contrary to what was expected, given the blood glucose lowering effectiveness of these drugs, 
SGLT2 inhibitor treatment did not increase the frequency of hypoglycemia in patients with 
T1D in all of the previously mentioned studies. 
Over the past few years of research, SGLT2 inhibitors have been associated with an 
increase in glucagon secretion, specifically in patients with T2D 4,5.  Furthermore, in 2015, 
Bonner et al. discovered the presence of SGLT2 on the a-cells in human islets, suggesting a 
possible mechanism by which these drugs could augment glucagon secretion 3. The in vivo 
effects of SGLT2 inhibition on glucagon secretion in T1D remain unknown. If these drugs act 
to increase glucagon secretion in patients with T1D, it is possible that this rise in glucagon 
secretion could prevent hypoglycemia by restoring some level of glucagon counterregulation. 
To test this idea, we administered 8 days of treatment with empagliflozin, an SGLT2 
inhibitor, to rats with streptozotocin-induced T1D and examined the effects on plasma 
glucose and glucagon concentrations during both insulin-induced hypoglycemia and 
voluntary exercise. Additionally, we used both male and female rats to test for any sex-related 
differences in the effects of SGLT2 inhibition. We hypothesized that there would be an 
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increase in plasma glucagon concentrations following SGLT2 inhibition during both insulin-
induced hypoglycemia and exercise for males and females alike.  
 
Methods 
Ethics Statement 
This study was carried out in accordance with the recommendations of the Canadian 
Council for Animal Care guidelines and was approved by the York University Animal Care 
Committee (Protocol 2017-16). 
 
Animals 
Thirty-three male and thirty-one female Wistar rats (bred in the York University vivarium, 
six weeks old) were housed in individual running wheel cages (Harvard Apparatus) with 
access to standard chow (Purina chow #5012) and water ad libitum. All animals were exposed 
to a 12h:12h light-dark cycle, 50-60% humidity, and temperatures between 22-23°C from 
birth. Prior to the start of the study, all rats were habituated to the running wheels with a full 7 
days of continuous, voluntary running wheel access.  
 
Experimental Design 
 
A complete timeline of the experimental protocol is shown in Figure 2.  
 
Diabetes Induction and Maintenance  
Diabetes was induced in all animals using an intraperitoneal injection of 65mg/kg 
streptozotocin (STZ) (CAS #18883-88-4, Sigma-Aldrich, St Louis, MO). To promote 
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diabetes induction, rats were fasted the night before injection and were given a 10% sucrose 
solution in their drinking water for 2 days following the injection. All running wheels were 
locked during this time to further promote diabetes. Tail capillary blood glucose levels were 
monitored daily to confirm diabetes using a sterile needle poke (30 gauge) and hand held 
glucose meter (CONTOURâ NEXT Meter). One week after diabetes induction, each rat 
received individualized insulin treatment to manage their blood glucose levels at a target 
range of 15-25mmol/L. A fraction (1/8-1) of a sustained release insulin pellet (Linplant pellet, 
~2U/24 hour/implant, LinShin Canada Inc.) was implanted subcutaneously under the dorsal 
skin while the animal was under isoflurane anesthetic. Linplant insulin pellets are designed to 
release a standard dosage of insulin in order to maintain blood glucose levels at a tolerable 
range and limit ketosis and glucosuria. Because potential b-cell regeneration can occur with 
STZ use in rodents 97,98, animals were excluded from this study if they reached a consistent 
basal morning blood glucose level of 11mmol/L or below at any point during this protocol. 
 
Animal Grouping and Running Wheel Re-habituation 
Rats were randomized into either an active group or an inactive group and then further 
separated into drug (10mg/kg empagliflozin [JardianceTM] dissolved in H2O) and placebo 
groups (H2O) (Figure 3). Rats in the inactive groups were prohibited from running by locking 
their wheels for the entirety of the study. The rats in the active groups were given voluntary 
running wheel access at various, predetermined times throughout the protocol. After diabetes 
induction, rats in the active groups were given 7 days of controlled but voluntary running 
wheel access daily from 5-9PM in order to habituate the animals to the running wheel 
exposure that they would be receiving in the following portion of the experiment. 
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SGLT2 Inhibitor Treatment and Voluntary Running Wheel Activity 
Animals were given 8 days of treatment (drug or placebo) via oral gavage, twice a day at 
9AM and 5PM. Tail blood glucose measurements were taken daily at 9AM, 10AM, 5PM, 
6PM and 9PM. These time points were chosen because of the tmax (1 hour) and half-life (1-6 
hours) of empagliflozin in rats 136.  
Throughout this treatment period, animals in the active groups were allowed 4 hours/day 
of voluntary running wheel access from 5PM to 9PM. This time restriction in running wheel 
activity was given to allow us to better monitor the effects of voluntary running wheel activity 
on blood glucose levels under the time window with the most prominent effects of SGLT2 
inhibition. This limited running wheel exposure also allowed us to determine if SGLT2 
inhibition influences voluntary wheel running behavior. Wheel revolutions were tracked with 
magnetic revolution counters and running distance was calculated using the running wheel 
circumference (106cm). During these 4 hours, food availability was limited to 10g in order to 
reduce variability in food intake and to promote voluntary wheel running 137.  For the purpose 
of measuring plasma glucagon concentrations, blood samples were taken via saphenous vein 
bleed (using a sterile needle puncture of the exposed vein after hair was trimmed) on the first 
and last day of treatment at 9PM (post-exercise), and on the fifth day of treatment at 9AM and 
10AM (pre and post treatment).   
 
Insulin-Induced Hypoglycemic ‘Challenge’ 
An insulin-induced hypoglycemic ‘challenge’ was administered on the day following 
the last day of SGLT2i treatment. Food was removed from all animal cages thirty minutes 
prior to the start of the hypoglycemic challenge, and animals remained fasted for the entirety 
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of this challenge. Thirty minutes after drug or placebo administration, all animals were 
injected with a subcutaneous bolus of insulin aspart (10U/kg, NovoRapidÒ, Novo Nordisk) in 
order to induce hypoglycemia (≤3.5mmol/L). Blood glucose concentrations were monitored 
throughout the challenge every 5-10 minutes via tail bleed. In order to investigate any 
changes in glucagon concentrations, blood samples were collected from the saphenous vein at 
set points prior to and during the challenge (Figure 4). When blood glucose reached ≤3.5 
mmol/L, rats were immediately anesthetized with inhaled isoflurane and additional blood 
samples were taken from the saphenous vein and from the portal vein. The animals were then 
killed via exsanguination.  
 
Plasma Analysis 
All blood samples were collected in potassium-EDTA coated microvette capillary tubes 
(Sarstedt, Des Grandes Prairies, Montreal, Québec, Canada, Cat #16.444.100) and 
immediately centrifuged (12,000 rpm for 5 minutes). The plasma was then extracted and 
stored in polyethylene tubes at -80°C for further analysis. Plasma glucagon concentrations 
were batch measured using a glucagon ELISA kit (Cat# 10-1271-01, Mercodia, Uppsala, 
Sweden). 
 
Statistical Analysis 
Data are reported as means ± standard deviations (SD). The ROUT method (GraphPad 
Prism 8.0) was used for all outlier identification. Data were analyzed using a two-way ANOVA, 
three-way ANOVA, three-way ANOVA with repeated measures, or a mixed effect model 
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(GraphPad Prism 8.0). Where appropriate, simple effects were examined and Tukey’s post hoc 
tests were conducted. The criteria for significance was set at p<0.05. 
 
Results 
 A total of fourteen animals were excluded from this study – eleven animals were 
excluded because of presumed b-cell regeneration (blood glucose levels reached a consistent 
morning measurement of 11mmol/L or below) and three animals died before completing the 
protocol. Causes of death are unknown. Data was analyzed from a total of twenty-seven male 
and twenty-three female animals. 
 
SGLT2 inhibition improved overall blood glucose control 
In order to confirm the effects of SGLT2 inhibition on overall blood glucose control, 
blood glucose measurements were taken daily at 9AM, 10AM, 5PM, 6PM, and 9PM, and 
averaged at each time point to obtain the mean daily blood glucose trend for each animal. 
Overall blood glucose data are displayed for males (Figure 5a) and females (Figure 5b), 
separately. In inactive, placebo treated animals, blood glucose concentrations remained 
hyperglycemic, with small but significant increases observed throughout the day. For 
placebo-treated males, blood glucose concentration was higher at 6PM (27.7±4.1 mmol/L) 
and 9PM (26.7±4.1 mmol/L) in comparison to their 9AM glucose level (24.8±3.6 mmol/L) 
(p=0.0009,  p=0.03, respectively). For placebo-treated, inactive females, blood glucose 
concentration was higher at 10AM (26.1±3.6 mmol/L), 6PM (26.5±3.1 mmol/L) and 9PM 
(27.9±2.8 mmol/L) in comparison to their 9AM glucose level (24.1±2.7 mmol/L) (p=0.01, 
p=0.046, p=0.008, respectively).  
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SGLT2 inhibition caused a significant decrease in overall blood glucose 
concentrations for both males (26.3±4.0 mmol/L vs 13.4±4.9 mmol/L, p<0.0001) and females 
(23.5±4.3 mmol/L vs 14.7±5.6 mmol/L, p<0.0001), with no obvious sex-related differences 
observed. No episodes of hypoglycemia were observed in any animal during these daily blood 
glucose checks. The effects of SGLT2 inhibition varied with time, depending on the time of 
day the treatment was given, as well as the amount of time that had passed since 
administration (p<0.0001). In comparison to the placebo treated group, SGLT2 inhibitor 
treatment caused a significant drop in blood glucose concentrations from 9AM to 10AM 
(+1.4±1.9 mmol/L vs -9.2±1.9 mmol/L, p<0.0001) (Figure 6). These effects continued to last 
until 5PM (8 hours post-gavage) in males specifically, where blood glucose levels remained 
significantly lower than 9AM measurements (19.6±3.6 mmol/L vs 14.0±3.9 mmol/L, 
p<0.0001) (Figure 5a). After a second treatment at 5PM, SGLT2 inhibition again caused a 
significant decrease in blood glucose concentrations, however by 9PM (4 hours post-gavage), 
blood glucose levels were no longer different than 5PM measurements in either males or 
females (Figures 5a and 5b).  
 
SGLT2 inhibition did not alter exercise-associated changes in blood glucose 
concentrations 
To investigate the effects of SGLT2 inhibition on blood glucose concentrations during 
exercise, blood glucose measurements were taken at 5PM, 6PM, and 9PM, while animals had 
voluntary access to running wheel activity. When examining the change in blood glucose 
during the four hours of habitual exercise (5PM-9PM), we found no effect of SGLT2 inhibitor 
treatment in comparison to vehicle treatment (Figure 7). However, we did find a significant 
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interaction of activity and sex (p=0.008). More specifically, four hours of voluntary wheel 
running caused a significant decrease in the blood glucose concentrations of female rats (-
2.9±2.6 mmol/L) in comparison to control (i.e. inactive) female rats (+1.7±1.8 mmol/L) 
(p=0.0003). This glucose lowering effect of exercise was not seen in male rats. Furthermore, 
in female animals alone, there was also a significant interaction of activity and time (p<0.05). 
Exercise lowered blood glucose concentrations specifically at 6PM (18.8±3.1 mmol/L vs 
14.8±2.9 mmol/L, p=0.01) and 9PM (22.9±2.8 mmol/L vs 15.9±3.9 mmol/L, p=0.001), 
during the time period where the animals had access to running wheels (Figure 5b). There 
was no correlation between average running distance and change in blood glucose levels from 
5PM-9PM (r2=0.02) (Figure 9).  
 
Voluntary running wheel activity was unaltered by SGLT2 inhibition 
 The mean running distances are displayed in Figure 8, with individual data points 
indicating the average daily running distance of each animal from 5-9PM. Outliers were 
excluded from all data analysis. According to our analysis, SGLT2 inhibition did not have a 
significant effect on voluntary running wheel activity. However, voluntary running wheel 
activity was affected by sex. On average, female animals ran significantly further than male 
animals over the four hours of voluntary wheel access (539.2±199.4 m vs 308.4±215.6 m, for 
female and male rats respectively, p=0.02).  
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Basal and post-exercise plasma glucagon concentrations were unaffected by SGLT2 
inhibition 
Plasma glucagon concentrations were measured at 9AM and 10AM on the 5th day of 
treatment in order to examine baseline effect of SGLT2 inhibition on glucagon secretion 
(Figure 10). Basal 9AM glucagon concentrations were unaffected by five days of SGLT2 
inhibition. However, there was a trend towards a significant interaction of sex and activity 
(p=0.06). Although this interaction did not quite meet our pre-selected threshold for 
significance, upon further investigation, we found that in physically active animals, basal 
9AM glucagon concentrations were significantly higher in males (65.0±32.2 pg/mL) than in 
females (27.1±9.8 pg/mL) (p=0.0009). Furthermore, physical activity tended to increase basal 
glucagon levels significantly in males (36.7±16.6 pg/mL vs 65.0±32.2 pg/mL, p=0.06) but not 
in females. SGLT2 inhibition also did not appear to affect the change in plasma glucagon 
concentrations from 9AM to 10AM in either sex (Figure 11). However, there was a 
significant main effect of previous physical activity on the change in glucagon levels during 
this time, which, on average, appeared to reduce the increase in glucagon that was seen in the 
inactive groups (+4.1±32.6 pg/mL vs +32.6±41.5 pg/mL, p=0.04).  
 Plasma glucagon concentrations were also measured post-exercise (9PM) on the first 
and last days of treatment, in order to examine the effects of SGLT2 inhibition on any 
exercise-associated changes in glucagon secretion, and to investigate any changes in these 
effects with prolonged SGLT2 inhibitor treatment. On the first day of treatment, there was no 
effect of SGLT2 inhibition on glucagon levels (Figure 12). We did, however, see a trend 
towards a significant interaction between activity and sex (p=0.05). Upon further 
investigation of this interaction, in female animals, exercise led to significantly lower plasma 
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glucagon concentrations in comparison to the glucagon concentrations of inactive animals at 
this time (117.9±86.0 pg/mL vs 37.3±47.9 pg/mL, p=0.01). There were no significant 
differences between 9PM glucagon levels on the first and last day of treatment (Figure 13). 
 
SGLT-2 inhibition did not prevent insulin-induced hypoglycemia 
Blood glucose concentrations were measured throughout the insulin-induced 
hypoglycemic challenge in both males (Supplementary Figure 1) and females 
(Supplementary Figure 2). Any animal with an initial blood glucose concentration of 
10mmol/L or below at the start of this challenge was excluded from all analyses. We first 
investigated the effects of SGLT2 inhibition at -30 minutes and at 0 minutes (with time 0 
representing insulin administration). In both male (Figure 14a) and female (Figure 14b) 
animals, there was a main effect of SGLT2 inhibition, which produced significantly lower 
overall blood glucose levels at the beginning of the challenge (Males: 23.5±5.3mmol/L vs 
13.1±6.3 mmol/L, p=0.0001) (Females: 23.1±5.9 mmol/L vs 16.1±6.1 mmol/L, p=0.03). In 
male animals, a drop in blood glucose levels was seen from -30 minutes to 0 minutes in 
SGLT2 inhibitor-treated animals (17.8±5.3 mmol/L vs 8.5±2.7 mmol/L, p<0.0001) but not in 
placebo-treated animals. Alternatively, in female animals, a drop in blood glucose levels from 
-30 minutes to 0 minutes was seen overall (22.6±6.2 mmol/L vs 17.1±6.5 mmol/L, p<0.0001). 
Time to hypoglycemia was calculated as the amount of time taken to reach a blood 
glucose concentration of £3.5 mmol/L after insulin injection (t=0 min) (Figure 15). After 
analysis using a three-way ANOVA, we found a significant interaction between treatment and 
sex (p=0.02). In males, SGLT2 inhibition significantly decreased time to hypoglycemia in 
comparison to the placebo group (63.8±17.2 min vs 30±13.4 min, p<0.0001). SGLT2 
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inhibition did not have a significant effect on time to hypoglycemia in female rats. However, 
for placebo-treated animals, time to hypoglycemia was significantly shorter in females 
compared to males (63.8±17.2 min vs 41.2±14.5 min, p=0.002). Activity did not appear to 
affect blood glucose levels during the insulin-induce hypoglycemic challenge or the time 
taken to reach hypoglycemia. 
 
SGLT2 inhibition may lower plasma glucagon response to insulin-induced hypoglycemia  
 To investigate the effects of SGLT2 inhibition on glucagon secretion during 
hypoglycemia, plasma glucagon concentrations were measured from the saphenous vein at set 
time points throughout the insulin-induced hypoglycemic challenge. Glucagon concentrations 
followed a similar trend in all groups for both males (Figure 16a) and females (Figure 16b). 
Baseline glucagon concentrations were defined as the concentrations at 0 minutes, 
immediately before insulin injection (Table 1). There were no significant differences in basal 
glucagon concentrations between groups. Glucagon concentrations at baseline were 
subtracted from all glucagon values during this challenge in order to analyze changes in these 
concentrations (Figure 16). Plasma glucagon concentrations significantly increased from 
baseline at euglycemia (4-6mmol/L) and hypoglycemia (£3.5mmol/L) for both males 
(Euglycemia: +63.8±57 pg/mL, p=0.0005; Hypoglycemia: +57.3±36.9 pg/mL, p<0.0001) and 
females (Euglycemia: +48.3±35.8 pg/mL, p<0.0001; Hypoglycemia: +30.7±47.7 pg/mL, 
p=0.04). Additionally, male animals showed significantly higher glucagon levels at -30 
minutes than at baseline (+14.8±12.9 pg/mL, p<0.0001).  
 A main effect of SGLT2 inhibition was seen in male animals but not in female 
animals. In males, SGLT inhibitor-treated groups has significantly smaller increases in 
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glucagon levels than placebo-treated groups (+40.4±48.6 pg/mL vs +22.7±30.8 pg/mL, 
p=0.02). There was no effect of SGLT2 inhibition on portal vein glucagon concentrations 
during hypoglycemia (Figure 17). However, a previous bout of physical activity appeared to 
increase portal vein glucagon concentrations during hypoglycemia in comparison to the 
inactive groups, with a trend towards statistical significance  (102.1±80.2 pg/mL vs 
152.4±150 pg/mL, p=0.05). 
 
Discussion 
 
We used a rat model of T1D to investigate the ability of SGLT2 inhibition to oppose 
the hypoglycemic effects of both physical activity and excess exogenous insulin, two 
scenarios that frequently cause hypoglycemia in individuals with T1D. Because SGLT2 
inhibition has been shown to increase the secretion of glucagon in both humans and mice with 
T2D, we hypothesized that SGLT2 inhibition would increase glucagon secretion in T1D as 
well. However, here we showed that these previously demonstrated effects of SGLT2 
inhibition on glucagon secretion may not extend to T1D and that SGLT2 inhibition alone did 
not help prevent or delay hypoglycemia. On the contrary, we found that, in male rats 
specifically, SGLT2 inhibition reduced the time to hypoglycemia, perhaps because baseline 
glucose levels were effectively lowered by the drug, and blunted the glucagon response to 
insulin-induced hypoglycemia. These findings do not support the notion that SGLT2 
inhibition helps protect against hypoglycemia in diabetes by increasing glucagon 
counterregulation. 
According to previous research, SGLT2 inhibition has been shown to increase fasting 
plasma glucagon concentrations in healthy mice one hour after a single dose of an SGLT2 
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inhibitor, and after 4 days of treatment 3. Additionally, both a single dose and a 4 week dose 
of SGLT2 inhibition increases post-meal plasma glucagon concentrations in humans with 
T2D for up to 5 hours 4. Contrary to what has been presented in the literature, we report here 
that SGLT2 inhibition does not appear to impact basal glucagon levels in rats with T1D. We 
demonstrated this lack of impact both acutely and chronically; 30 minutes post drug 
administration (during the insulin-induced hypoglycemic challenge), 1 hour post drug 
administration (at 10AM on the fifth day of treatment), 4 hours post drug administration (at 
9PM on the first and last days of treatment), and basal measurements after 4 full days of 
treatment (9AM on the fifth day of treatment). Our findings here appear to challenge the idea 
that SGLT2 inhibitors act directly on a-cells to augment glucagon secretion 3,6. Previous 
studies that have shown an SGLT2 inhibitor-induced increase in glucagon secretion were 
performed in circumstances where b-cells were present 3–5,127,128. In comparison, we used a 
high dose of STZ to induce severe b-cell loss in our animals to model what occurs in T1D. 
Some studies have suggested that b-cell secretions may play a central role in the regulation of 
glucagon secretion 138. Therefore, a possible explanation for the lack of effect of SGLT2 
inhibition on glucagon secretion presented in our results may be related to some level of b-
cell interaction that is not present in T1D. However, in a study examining the effects of 
dapagliflozin in rodent models of T2D, Wang et al proposed that the lack of a significant 
change in plasma glucagon concentrations that they observed may be due to a combination of 
a decrease in glucagon secretion and a reduced sequestering of glucagon by the liver 7. These 
researchers also found decreases in glucagon production from dapagliflozin-treated perfused 
pancreata that originated from STZ-treated type 1 diabetic rats, and glucagon-producing cells 
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treated with siRNA that targets SGLT2. According to this one study, intact islets may not be 
necessary for augmentations in glucagon secretion in response to SGLT2 inhibition.  
Another possible explanation for the observed lack of effect of SGLT2 inhibition on 
plasma glucagon concentrations may be related to our specific model of T1D. One of the 
limitations of our study was the chronic state of hyperglycemia experienced by all animals. 
We maintained hyperglycemic blood glucose levels in our animals because previous research 
has shown that improved glycemic control in STZ-induced diabetes can induce b-cell 
regeneration 97,98. In a study published in 2007, Abdul-Ghani and Defronzo proposed a 
glucotoxic effect of chronic hyperglycemia on the glucose-mediated suppression of glucagon 
secretion from a-cells 139. If this is indeed the case, it may explain the lack of effect of 
SGLT2 inhibition on plasma glucagon concentrations that we observed in our study, since the 
effects of SGLT2 inhibition on a-cells would be dependent on the response of these cells to 
glucose.  
 We demonstrated that SGLT2 inhibition did not affect plasma glucagon 
concentrations post-exercise. Furthermore, SGLT2 inhibition did not significantly alter 
exercise-associated changes in blood glucose concentrations. According to these results, it 
appears as though the effects of exercise and the effects of SGLT2 inhibition were 
independent of one another. Because the blood glucose levels of our animals were maintained 
at hyperglycemia, voluntary exercise did not cause a large enough decrease in these levels to 
induce hypoglycemia and we could not analyze the effects of SGLT2 inhibition on exercise-
induced hypoglycemia directly, as we have done with other new therapeutic options for 
hypoglycemia protection in diabetes 140. However, we did measure the effects of SGLT2 
inhibition on insulin-induced hypoglycemia and again, we found no obvious improvement on 
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glucagon counterregulation with the therapeutic agent. During the insulin-induced 
hypoglycemic challenge, we showed that SGLT2 inhibition alone, without appropriate 
adjustments to exogenous insulin intake, did not prevent insulin-induced hypoglycemia. 
Furthermore, male animals treated with an SGLT2 inhibiter reached hypoglycemia faster, and 
had a decrease in overall glucagon levels during the challenge. Unfortunately, some of our 
sample sizes were too small to confidently determine if this effect extends to females as well. 
Given the independent blood glucose lowering mechanisms of SGLT2 inhibitors and insulin, 
it would be logical to expect a compounded effect on glucose clearance from the blood 
stream. However, the decrease in plasma glucagon concentrations that we observed may 
represent a direct action of SGLT2 inhibition on a-cells during hypoglycemia. These results 
are in line with a study performed by Pedersen et al, which demonstrated a trend towards a 
decreased glucagon secretion in human pancreatic islets exposed to a glucose concentration of 
1mmol/L 6. Additionally, in 2017, Wang et al demonstrated that SGLT2 inhibition suppressed 
glucagon secretion in perfused pancreata from rats with STZ-induced T1D, at a glucose 
concentration of 2.5mmol/L 7. Although the research is limited, our results appear to support 
the idea that SGLT2 inhibition decreases glucagon response to hypoglycemia, contrary to our 
initial hypothesis. This could represent a concerning side effect of SGLT2 inhibitors to 
patients with T1D as well as T2D patients treated with insulin or sulfonylureas, who are 
already at risk of hypoglycemia. Further research is needed to determine the effects of SGLT2 
inhibition on glucagon counterregulation to hypoglycemia in humans with T1D. 
In addition to our primary outcome, we demonstrated some other interesting and 
unanticipated findings. A common theme throughout this study was an interaction between 
sex and activity. Consistent with previous research which has demonstrated increased 
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voluntary locomotor activity in female Wistar rats compared to males 141, we showed larger 
voluntary running distances in females. Most notably, we also found that voluntary running 
wheel activity decreased blood glucose levels in female rats at 6PM and 9PM, whereas this 
effect of physical activity was not seen in male rats. However, since we showed no correlation 
between running distance and changes in blood glucose concentrations during exercise for 
either sex, we cannot attribute the sex differences we observed in exercise-associated blood 
glucose changes to differences in running wheel activity. We reason that there must be an 
alternative sex-specific mechanism behind these differences in blood glucose response to 
voluntary physical activity.  
At their simplest, changes in blood glucose concentrations are a result of changes to 
the ratio of the rate of glucose appearance (Ra) to the rate of glucose disappearance (Rd). 
Because we did not observe any significant effects of exercise on blood glucose 
concentrations in males, the ratio of Ra to Rd must not have been affected by exercise in these 
animals. Following this idea, either exercise did not significantly increase Rd in these 
animals, or there was a sufficient amount of counterregulation to balance out an increased 
glucose uptake. In our protocol, glucagon was not affected by a bout of exercise in the male 
animals. However, past research has shown significant differences in the counterregulatory 
abilities of males and females to moderate physical activity, in counterregulatory hormones 
other than glucagon. This counterregulatory response has generally been shown to be higher 
in males than in females, in hormones such as epinephrine, norepinephrine, growth hormone, 
and cortisol, both in healthy individuals 68–70 and individuals with T1D 142,143. These 
counterregulatory hormones were not measured in our study, but may play a role in the sex 
differences that we observed.  
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Contrary to what we observed in the males rats, a bout of voluntary physical activity 
caused a significant decrease in the blood glucose levels of female rats, indicating that this 
exercise must have been associated with an increased Rd, a decreased Ra, or both. An 
increased Rd in female rats could be related to estrogen signalling, which has been implicated 
in skeletal muscle adaptations to exercise 144. Activation of estrogen receptors in rats has also 
been shown to lead to an increased skeletal muscle insulin-induced glucose uptake 145. On the 
other hand, we showed that physical activity lowered post-exercise glucagon concentrations 
in female rats, which would be expected to lead to a decreased Ra. The sex differences that 
we observed in post-exercise glucagon levels are intriguing. Previous research in non-diabetic 
individuals has shown an increased glucagon counterregulatory response to insulin-induced 
hypoglycemia in males compared to females 71,72. Research on sex differences related to 
glucagon secretion in T1D, however, is lacking. Because glucagon response to hypoglycemia 
is known to be blunted in T1D, this may overshadow any potential sex differences in 
glucagon secretion that still exist in these patients. 143. One study examined sex differences in 
glucagon secretion during euglycemic exercise in patients with T1D, but did not find any 
significant differences 142. As far as we know, this is the first study to examine sex differences 
in exercise-associated changes to blood glucose and glucagon concentrations in T1D. This 
gap in knowledge has recently been acknowledges in the literature, where it has been 
suggested that females may have a greater defense in blood glucose control after exercise than 
men 146,147.  Possible explanations for this suggestion come from studies showing that healthy 
females appear to have an increased sensitivity to the lipolytic actions of counterregulatory 
hormones 148, and are able to regain control over post-exercise glycaemia more quickly than 
men 149. However, our study suggests that females with T1D may instead have a weaker 
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defense to exercise-induced decreases in blood glucose concentrations. These results may 
have important implications relating to sex differences in exercise-associated changes in 
blood glucose concentrations that do not lead to hypoglycemia for individuals with T1D. 
We also feel that it is also important to acknowledge that in females, an exercise-
associated drop in blood glucose concentrations was associated with a change in glucagon 
levels, whereas an SGLT2 inhibitor associated drop in blood glucose levels was not. This 
observation suggests that, in our protocol, blood glucose concentrations themselves were not 
the primary regulator of glucagon secretion. We propose that the reduction in post-exercise 
glucagon concentrations that we observed may instead reflect an increased carbohydrate 
uptake and a decrease in the fasted state of the animals. 
In conclusion, we demonstrated that SGLT2 inhibition does not appear to alter basal 
glucagon concentrations in T1D, but may reduce the glucagon response to hypoglycemia. 
However, because of the chronic state of hypoglycemia in our animals, and our limited 
sample sizes, these results should be interpreted cautiously. Since rates of hypoglycemia are 
already high in individuals with T1D, our results may represent a concerning side effect of 
SGLT2 inhibition. Further research into the effects of SGLT2 inhibitor treatment on the 
glucagon response to hypoglycemia in individuals with T1D is warranted. Furthermore, we 
also demonstrated novel sex differences in exercise-associated changes in blood glucose and 
glucagon concentrations in rodents with T1D. Additional research is needed to determine the 
mechanisms behind these observed differences and to confirm whether or not these results 
translate to human with T1D. 
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Week 1 Week 5 Week 4 Week 3 Week 2 Week 0 
Diabetes 
Induction 
Insulin pellet 
implantation  
Hypoglycemic 
challenge 
 
Drug  
administration  
with RW access 
RW  
Habituation 
 
RW  
Re-habituation 
 
Figure 2: Experimental design. Running wheel is abbreviated as RW. After running wheel habituation, the 
experimental protocol consisted of 4 main weeks followed by an insulin-induced hypoglycemic challenge at the 
beginning of week 5. Red droplets indicate saphenous vein blood sample collection on the first and last day of drug 
treatment (9PM) and midway through the treatment (9AM and 10AM). 
Wistar rats  
Males (n=27)    Females (n=23) 
Inactive Active 
STZ  
(65 mg/kg) 
Drug  
Males (n=7) 
Females (n=4) 
Diabetic 
Placebo  
Males (n=7) 
Females (n=8) 
Figure 3: Animal grouping. All Wistar rats were made diabetic using an intraperitoneal injection of streptozotocin 
(STZ) at a dose of 65mg/kg. Animals were then randomly divided into four groups: Inactive Placebo [Male (n=6), 
Female (n=7)], Inactive with Drug [Male (n=7), Female (n=4)], Active Placebo [Male (n=7), Female (n=8)], and 
Active with Drug [Male (n=7), Female (n=4)].  
Drug  
Males (n=7) 
Females (n=4) 
Placebo  
Males (n=6) 
Females (n=7) 
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Saphenous vein blood sample  
Drug/Placebo 
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(10U/kg) 
-30 min 
 Blood glucose measured every 5-10 minutes  
0 min Blood glucose  
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Blood glucose  
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Figure 4: Insulin-induced hypoglycemic challenge protocol. A subcutaneous injection of insulin aspart 
(10U/kg) was administered 30 minutes after regular morning drug administration. Bright and dark red droplets 
indicate blood samples taken for glucagon analysis from the saphenous vein and portal vein, respectively. Blood 
samples were taken immediately before drug/placebo administration (-30 minutes), before insulin injection (0 
minutes), when blood glucose levels reached euglycemia (4-6mmol/L), and when blood glucose levels reached 
hypoglycemia upon anesthetization (£3.5mmol/L). Blood glucose concentrations were measured every 5-10 
minutes via tail vein bleed. 
 
Portal vein blood sample  
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a) 
b) 
Figure 5: Average daily blood glucose levels were improved with SGLT2 inhibition in males (a) and females (b). 
Treatment was given by oral gavage twice a day at 9AM and 5PM (vertical dotted lines). Animals in active groups had 
daily access to voluntary wheel running from 5PM-9PM (grey shaded area). Optimal blood glucose levels were defined 
as 5-8mmol/L (shaded green area). All data are expressed as mean ± SD. **** p<0.0001 for main effect of treatment, # 
p<0.05 compared to 9AM, † p<0.05 compared to 5PM, * p<0.05 for simple effect of activity at 6PM, ** p<0.01 for 
simple effect of activity at 9PM. 
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Figure 7: Physical activity lowered blood glucose concentrations from 5PM-9PM in females but not males.  
Animals in active groups were given 4 hours of voluntary wheel running from 5PM to 9PM, daily. Treatment was 
administered at 5PM immediately before running wheel access was given. SGLT2 inhibition did not alter change in 
blood glucose concentrations during exercise. Data are expressed as mean ± SD. *** p<0.001 for simple effect of 
activity. 
Figure 6: SGLT2 inhibition lowered blood glucose concentrations from 9AM to 10AM. Blood glucose 
concentrations were measured immediately before treatment was administered (9AM) and 1 hour post-treatment 
(10AM). Data are expressed as mean ± SD. **** p<0.0001 compared to placebo. 
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Figure 8: Voluntary running wheel activity was unaltered by SGLT2 inhibition but greater in females than 
males. Average daily running distance from 5PM-9PM. Solid dots represent the daily averages of each individual 
animal. Open dots represent outliers, which were excluded from all data analyses. Data are expressed as mean ± SD  
* p<0.05 compared to males. 
Figure 9: Voluntary running wheel activity was not correlated with change in blood glucose concentration 
during exercise. Data was analyzed using the daily running distances and changes in blood glucose concentrations of 
animals from 5PM-9PM for active placebo groups alone (r2=0.02). Blue dots represent measurements taken from a 
single animal on a single day. 
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Figure 10: Basal glucagon concentrations were higher in physically active males than physically active females. 
Basal glucagon measurements were taken at 9AM on day 5 of treatment, immediately before treatment (after 4 full 
days of treatment). SGLT2 inhibition did not affect basal glucagon levels. Data are expressed as mean ± SD. *** 
p<0.001 for simple effect of sex in active animals, p=0.06 for simple effect of activity in males. 
Figure 11: Changes in morning glucagon concentrations were reduced in physically active animals. Glucagon 
measurements were taken on day 5 of treatment at 9AM, immediately before treatment, and at 10AM, 1 hour after 
treatment. SGLT2 inhibition did not cause a change glucagon levels. Data are expressed as mean ± SD. * p<0.05 
compared to inactive animals. 
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Figure 12: Post-exercise glucagon concentrations were reduced in physically active females but not physically 
active males. Glucagon measurements were taken on the first day of treatment at 9PM following 4 hours of voluntary 
wheel running. SGLT2 inhibition did not affect post-exercise glucagon levels. Data are expressed as mean ± SD.  
* p<0.05 for simple effect of activity.  
Figure 13: Prolonged SGLT2 inhibitor treatment did not alter glucagon concentrations. Glucagon measurements 
were taken on the first and last day of treatment at 9PM, 4 hours after treatment administration. Data are expressed as 
mean ± SD.  
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†††† 
 
Figure 14: Blood glucose concentrations during the insulin-induced hypoglycemic challenge for males (a) and 
females (b). Regular morning treatment was given at -30 minutes and insulin aspart (10U/kg) was injected 
subcutaneously at 0 minutes. Animals were anesthetized once hypoglycemic. The horizontal black dotted line 
indicates hypoglycemia at £3.5 mmol/L. Horizontal error bars indicate SD for mean time to hypoglycemia. A three-
way ANOVA with repeated measures was performed using only the -30 and 0 time points. Data are expressed as mean 
± SD. **** p<0.0001 for main effect of treatment, †††† p<0.0001 compared to -30 minutes, * p<0.05 for main effect 
of treatment, #### p<0.0001 for main effect of time. 
 
a) 
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 PLACEBO DRUG 
Inactive Active Inactive Active 
MALE 11.0±6.0 22.8±18.7 33.8±23.9 11.7±6.5 
FEMALE 16.4±27.5 31.6±58.3 10.2±3.7 20.5±17.4 
Figure 15: Time to hypoglycemia was decreased in males treated with an SGLT2 inhibitor. Time to 
hypoglycemia was  measured as the time taken to reach a blood glucose concentration of £3.5 mmol/L after insulin 
injection (t=0). Data are expressed as mean ± SD. **** p<0.0001 for simple effect of treatment, ** p<0.01 for simple 
effect of sex.  
 
Table 1: Basal glucagon concentrations during the insulin-induced hypoglycemic challenge. Plasma glucagon 
samples were taken from the saphenous vein immediately before insulin injection (0 minutes). Data are expressed as 
mean ± SD (pg/mL).  
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Figure 16: SGLT2 inhibition lowered changes in glucagon concentration in males (a) during the insulin-induced 
hypoglycemic challenge, but not in females (b). Treatment was administered at -30 minutes and insulin aspart 
(10U/kg) was injected subcutaneously at 0 minutes. Plasma glucagon samples were taken from the saphenous vein 
immediately before treatment (-30 minutes) and before insulin injection (0 minutes), as well as at euglycemia (4-
6mmol/L) and hypoglycemia (£3.5mmol/L) Data was calculated as change from baseline (0 minutes) and are 
expressed as mean ± SD. * p<0.05 for main effect of treatment. Matched letters indicate insignificant differences 
between time points. All time points without matched letters are significantly different from one another (p<0.05).  
 
£ 
£ 
a) 
b) 
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Figure 17: Portal vein glucagon concentrations at hypoglycemia were not affected by SGLT2 inhibition. Portal 
vein blood samples were taken while animals were under anesthesia, immediately after the insulin-induced 
hypoglycemic challenge when blood glucose concentrations were £3.5 mmol/L. Data are expressed as mean ± SD. 
p=0.05 for main effect of activity.  
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6. SUMMARY OF FINDINGS AND FUTURE DIRECTIONS    
 
We investigated the effects of SGLT2 inhibition on glucagon secretion and on changes in 
blood glucose concentrations during physical activity and insulin-induced hypoglycemia, in a 
rodent model of T1D. Our findings demonstrate that SGLT2 inhibition does not affect basal 
glucagon concentrations or post-exercise glucagon levels in type 1 diabetic rats. However, 
one of our limitations was the chronic hyperglycemia state of all animals, which could have 
potentially hidden the effect of this drug on glucagon secretion. Furthermore, the 
hyperglycemic state of our animals prevented us from being able to examine the effects of 
SGLT2 inhibition during exercise-induced hypoglycemia. Because the STZ-induced diabetic 
model that we chose to use may not be ideal for studies involving chronic euglycemia, it may 
be wise to repeat our study in another rodent model of T1D.  
Additionally, we found that, in male rats with T1D, SGLT2 inhibition reduces the 
glucagon counterregulatory response to insulin-induced hypoglycemia and accelerates the 
time taken to reach hypoglycemia. Because of our less than ideal sample sizes, specifically in 
SGLT2 inhibitor-treated female animals, we could not confidently determine if these results 
applied to females as well. Additional animals are needed in order to establish if this decrease 
in glucagon secretion is sex-specific. It would also be beneficial to test for SGLT-2 inhibitor-
associated changes in glucagon secretion in humans with T1D, since clinical trials are 
currently underway.  
 Unexpectedly, we uncovered sex differences in blood glucose and glucagon response 
to exercise. We showed that female rats with T1D respond to voluntary physical activity with 
a drop in both blood glucose levels and glucagon concentration, whereas males are unaffected 
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by voluntary physical activity in these regards. Although the difference in glucagon 
concentrations that we observed might explain the differing blood glucose responses, other 
counterregulatory hormones could have played a role as well. These sex differences should be 
further investigated and other counterregulatory hormones should be measured as well. 
Moreover, future studies should investigate whether these sex differences to exercise in T1D 
apply to humans as well.  
 Overall, our findings have important and potentially concerning implications for the 
use of SGLT2 inhibitors in T1D, and have also revealed sex differences in blood glucose 
response to exercise in rodent with T1D. Additional studies using larger sample sizes, 
euglycemic conditions, and clinical trials would give us a clearing and broader understanding 
of our finding and their possible applications.   
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Supplementary Figure 1: Blood glucose concentrations of male animals during the insulin-induced hypoglycemic challenge. 
Blood glucose measurements are shown for individual animals throughout the insulin-induced hypoglycemic challenge (mmol/L). 
Drug (10mg/kg empagliflozin) or placebo treatment (H2O) was given at -30 minutes via oral gavage and insulin aspart (10U/kg) was 
injected subcutaneously at 0 minutes, as indicated. Time to hypoglycemia was calculated as the minutes taken to reach a blood 
glucose measurement of £3.5 mmol/L. 
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Supplementary Figure 2: Blood glucose concentrations of female animals during the insulin-induced hypoglycemic 
challenge. Blood glucose measurements are shown for individual animals throughout the insulin-induced hypoglycemic 
challenge (mmol/L). Drug (10mg/kg empagliflozin) or placebo treatment (H2O) was given at -30 minutes via oral gavage and 
insulin aspart (10U/kg) was injected subcutaneously at 0 minutes, as indicated. Time to hypoglycemia was calculated as the 
minutes taken to reach a blood glucose measurement of £3.5 mmol/L. 
 
63 
 64 
8.    REFERENCES           
 
1.  Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal 
function and blood pressure. Diabetologia. 2018;61(10):2098-2107. 
doi:10.1007/s00125-018-4669-0 
2.  Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose co-
transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: 
Systematic review and meta-analysis of randomized controlled trials. Diabetes, Obes 
Metab. 2018;20(7):1755-1761. doi:10.1111/dom.13260 
3.  Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 
with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 
2015;21(5):512-517. doi:10.1038/nm.3828 
4.  Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose 
cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-
508. doi:10.1172/JCI72227 
5.  Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin 
sensitivity but enhances endogenous glucose production. J Clin Invest. 
2014;124(2):509-514. doi:10.1172/JCI70704 
6.  Pedersen MG, Ahlstedt I, El Hachmane MF, et al. Dapagliflozin stimulates glucagon 
secretion at high glucose: experiments and mathematical simulations of human A-cells. 
Sci Rep. 2016;6(August):31214. doi:10.1038/srep31214 
7.  Wang M, Yu X, Lee Y, et al. Dapagliflozin suppresses glucagon signaling in rodent 
models of diabetes. Proc Natl Acad Sci. 2017;114(25):6611-6616. 
 65 
doi:10.1073/pnas.1705845114 
8.  Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks 
and benefits. Diabetologia. 2018;61(10):2118-2125. doi:10.1007/s00125-018-4663-6 
9.  Gaisano HY, MacDonald PE, Vranic M. Glucagon secretion and signaling in the 
development of diabetes. Front Physiol. 2012;3:349. doi:10.3389/fphys.2012.00349 
10.  Henquin J-C. Perspectives in Diabetes Triggering and Amplifying Pathways of 
Regulation of Insulin Secretion by Glucose. Vol 49.; 2000. 
http://diabetes.diabetesjournals.org/content/diabetes/49/11/1751.full.pdf. Accessed 
October 27, 2018. 
11.  Rudenski AS, Hosker JP, Burnett MA, Matthews DR, Turner RC. The beta cell 
glucose stimulus-response curve in normal humans assessed by insulin and C-peptide 
secretion rates. Metabolism. 1988;37(6):526-534. 
http://www.ncbi.nlm.nih.gov/pubmed/3287091. Accessed October 27, 2018. 
12.  Sprague JE, Arbeláez AM. Glucose counterregulatory responses to hypoglycemia. 
Pediatr Endocrinol Rev. 2011;9(1):463-73; quiz 474-5. 
http://www.ncbi.nlm.nih.gov/pubmed/22783644. Accessed October 31, 2018. 
13.  Watts M, Ha J, Kimchi O, Sherman A. Paracrine regulation of glucagon secretion: the 
β/α/δ model. Am J Physiol Metab. 2016;310(8):E597-E611. 
doi:10.1152/ajpendo.00415.2015 
14.  Gylfe E, Gilon P. Glucose regulation of glucagon secretion. Diabetes Res Clin Pract. 
2014;103(1):1-10. doi:10.1016/j.diabres.2013.11.019 
15.  Marroquí L, Alonso-Magdalena P, Merino B, Fuentes E, Nadal A, Quesada I. Nutrient 
regulation of glucagon secretion: involvement in metabolism and diabetes. Nutr Res 
 66 
Rev. 2014;27(01):48-62. doi:10.1017/S0954422414000031 
16.  Heimberg H, De Vos A, Pipeleers D, Thorens B, Schuit F. Differences in glucose 
transporter gene expression between rat pancreatic alpha- and beta-cells are correlated 
to differences in glucose transport but not in glucose utilization. J Biol Chem. 
1995;270(15):8971-8975. http://www.ncbi.nlm.nih.gov/pubmed/7721807. Accessed 
October 28, 2018. 
17.  Ostenson CG. Regulation of glucagon release: effects of insulin on the pancreatic A2-
cell of the guinea pig. Diabetologia. 1979;17(5):325-330. 
http://www.ncbi.nlm.nih.gov/pubmed/387506. Accessed October 28, 2018. 
18.  Rorsman P, Berggren P-O, Bokvist K, et al. Glucose-inhibition of glucagon secretion 
involves activation of GABAA-receptor chloride channels. Nature. 
1989;341(6239):233-236. doi:10.1038/341233a0 
19.  Zhou H, Zhang T, Harmon JS, Bryan J, Robertson RP. Zinc, Not Insulin, Regulates the 
Rat  -Cell Response to Hypoglycemia In Vivo. Diabetes. 2007;56(4):1107-1112. 
doi:10.2337/db06-1454 
20.  Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin 
Invest. 1987;79(3):777-781. doi:10.1172/JCI112884 
21.  Gerich JE, Charles MA, Grodsky GM. Characterization of the effects of arginine and 
glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest. 
1974;54(4):833-841. doi:10.1172/JCI107823 
22.  Hope KM, Tran POT, Zhou H, Oseid E, Leroy E, Robertson RP. Regulation of alpha-
cell function by the beta-cell in isolated human and rat islets deprived of glucose: the 
 67 
&quot;switch-off&quot; hypothesis. Diabetes. 2004;53(6):1488-1495. 
doi:10.2337/DIABETES.53.6.1488 
23.  Olsen HL, Theander S, Bokvist K, Buschard K, Wollheim CB, Gromada J. Glucose 
Stimulates Glucagon Release in Single Rat α-Cells by Mechanisms that Mirror the 
Stimulus-Secretion Coupling in β-Cells. Endocrinology. 2005;146(11):4861-4870. 
doi:10.1210/en.2005-0800 
24.  Braun M, Ramracheya R, Bengtsson M, et al. Aminobutyric Acid (GABA) Is an 
Autocrine Excitatory Transmitter in Human Pancreatic-Cells. 2010. doi:10.2337/db09-
0797 
25.  Salehi A, Vieira E, Gylfe E. Paradoxical Stimulation of Glucagon Secretion by High 
Glucose Concentrations. Diabetes. 2006;55(8):2318-2323. doi:10.2337/db06-0080 
26.  Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the 
controversy. Metabolism. 1978;27(11):1691-1709. 
http://www.ncbi.nlm.nih.gov/pubmed/360007. Accessed November 22, 2018. 
27.  Walker JN, Ramracheya R, Zhang Q, Johnson PR V., Braun M, Rorsman P. 
Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes, 
Obes Metab. 2011;13:95-105. doi:10.1111/j.1463-1326.2011.01450.x 
28.  Hauge-Evans AC, King AJ, Carmignac D, et al. Somatostatin Secreted by Islet  -Cells 
Fulfills Multiple Roles as a Paracrine Regulator of Islet Function. Diabetes. 
2009;58(2):403-411. doi:10.2337/db08-0792 
29.  Gerich JE. Role of the kidney in normal glucose homeostasis and in the 
hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 
2010;27(2):136-142. doi:10.1111/j.1464-5491.2009.02894.x 
 68 
30.  Wasserman DH. Four grams of glucose. Am J Physiol Metab. 2009;296(1):E11-E21. 
doi:10.1152/ajpendo.90563.2008 
31.  Unger RH. Glucoregulatory hormones in health and disease. A teleologic model. 
Diabetes. 1966;15(7):500-506. doi:10.2337/DIAB.15.7.500 
32.  Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic 
illnesses. Diabetes. 1971;20(12):834-838. doi:10.2337/DIAB.20.12.834 
33.  Parrilla R, Goodman MN, Toews CJ. Effect of glucagon: insulin ratios on hepatic 
metabolism. Diabetes. 1974;23(9):725-731. doi:10.2337/DIAB.23.9.725 
34.  Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 
selectively in muscle causes insulin resistance and glucose intolerance. Nat Med. 
2000;6(8):924-928. doi:10.1038/78693 
35.  Thong FSL. Turning Signals On and Off: GLUT4 Traffic in the Insulin-Signaling 
Highway. Physiology. 2005;20(4):271-284. doi:10.1152/physiol.00017.2005 
36.  Andersen P, Saltin B. Maximal perfusion of skeletal muscle in man. J Physiol. 
1985;366(1):233-249. doi:10.1113/jphysiol.1985.sp015794 
37.  Proctor DN, Shen PH, Dietz NM, et al. Reduced leg blood flow during dynamic 
exercise in older endurance-trained men. J Appl Physiol. 1998;85(1):68-75. 
doi:10.1152/jappl.1998.85.1.68 
38.  Sjoberg KA, Rattigan S, Hiscock N, Richter EA, Kiens B. A new method to study 
changes in microvascular blood volume in muscle and adipose tissue: real-time 
imaging in humans and rat. AJP Hear Circ Physiol. 2011;301(2):H450-H458. 
doi:10.1152/ajpheart.01174.2010 
39.  Inyard AC, Clerk LH, Vincent MA, Barrett EJ. Contraction stimulates nitric oxide-
 69 
independent microvascular recruitment and increases muscle insulin uptake. Diabetes. 
2007;56(9):2194-2200. doi:10.2337/db07-0020 
40.  Zinker BA, Lacy DB, Bracy DP, Wasserman DH. Role of glucose and insulin loads to 
the exercising limb in increasing glucose uptake and metabolism. J Appl Physiol. 
1993;74(6):2915-2921. doi:10.1152/jappl.1993.74.6.2915 
41.  Wojtaszewski JFP, Higaki Y, Hirshman MF, et al. Exercise Modulates Postreceptor 
Insulin Signaling and Glucose Transport in Muscle-Specific Insulin Receptor Knockout 
Mice. Vol 104.; 1999. doi:10.1172/JCI7961 
42.  Ploug T, Galbo H, Richter E a. Increased muscle glucose uptake during contractions: 
no need for insulin. Am J Physiol. 1984;247(October):E726-E731. 
doi:10.2337/diabetes.34.10.1041 
43.  Ortega JF, Fernández-Elías VE, Hamouti N, García-Pallarés J, Mora-Rodriguez R. 
Higher insulin-sensitizing response after sprint interval compared to continuous 
exercise. Int J Sports Med. 2015;36(3):209-214. doi:10.1055/s-0034-1389942 
44.  Ren JM, Semenkovich CF, Gulve EA, Gao J, Holloszy JO. Exercise induces rapid 
increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated 
glycogen storage in muscle. J Biol Chem. 1994;269(20):14396-14401. 
doi:10.1210/me.2009-0437 
45.  Host HH, Hansen P a, Nolte L a, Chen MM, Holloszy JO. Glycogen 
Supercompensation Masks the Effect of a Traininginduced Increase in GLUT-4 on 
Muscle Glucose Transport. Vol 85.; 1998. doi:10.1152/jappl.1998.85.1.133 
46.  Wasserman DH, Geer RJ, Rice DE, et al. Interaction of exercise and insulin action in 
humans. Am J Physiol. 1991;260(1 Pt 1):E37-45. doi:10.1152/ajpendo.1991.260.1.E37 
 70 
47.  Wasserman DH. Regulation of Glucose Fluxes During Exercise in the Postabsorptive 
State. Annu Rev Physiol. 1995;57(1):191-218. 
doi:10.1146/annurev.ph.57.030195.001203 
48.  Cryer P. Hierarchy of Physiological Responses to Hypoglycemia: Relevance to 
Clinical Hypoglycemia in Type I (Insulin Dependent) Diabetes Mellitus*. Horm Metab 
Res. 1997;29(03):92-96. doi:10.1055/s-2007-978997 
49.  Marliss EB, Simantirakis E, Miles PD, et al. Glucose turnover and its regulation during 
intense exercise and recovery in normal male subjects. Clin Invest Med. 
1992;15(5):406-419. http://www.ncbi.nlm.nih.gov/pubmed/1458713. Accessed 
October 29, 2018. 
50.  Marliss EB, Vranic M. Intense exercise has unique effects on both insulin release and 
its roles in glucoregulation: Implications for diabetes. Diabetes. 
2002;51(SUPPL.):S271-83. doi:10.2337/diabetes.51.2007.S271 
51.  Lawrence RD. Renal Threshold for Glucose: Normal and in Diabetics. Br Med J. 
1940;1(4140):766-768. http://www.ncbi.nlm.nih.gov/pubmed/20783091. Accessed 
October 29, 2018. 
52.  Munguía-Miranda C, Sánchez-Barrera RG, Tuz K, Alonso-García AL, Cruz M. 
[Impaired fasting glucose detection in blood donors population]. TT – Deteccion de 
glucosa en ayuno alterada en donadores de sangre. Rev médica del Inst Mex del Seguro 
Soc. 2009;47(1):17-24. http://www.ncbi.nlm.nih.gov/pubmed/19624959. Accessed 
October 15, 2018. 
53.  Kuhl J, Hilding A, Ostenson CG, Grill V, Efendic S, Bavenholm P. Characterisation of 
subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes 
 71 
Prevention Programme: the impact of sex and type 2 diabetes heredity. Diabetologia. 
2005;48(1):35-40. doi:10.1007/s00125-004-1614-1 
54.  Clausen JO, Borch-Johnsen K, Ibsen H, et al. Insulin sensitivity index, acute insulin 
response, and glucose effectiveness in a population-based sample of 380 young healthy 
Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style 
factors. J Clin Invest. 1996;98(5):1195-1209. doi:10.1172/JCI118903 
55.  Lundsgaard A-M, Kiens B. Gender differences in skeletal muscle substrate metabolism 
- molecular mechanisms and insulin sensitivity. Front Endocrinol (Lausanne). 
2014;5:195. doi:10.3389/fendo.2014.00195 
56.  Klip A, Pâquet MR. Glucose transport and glucose transporters in muscle and their 
metabolic regulation. Diabetes Care. 1990;13(3):228-243. 
doi:10.2337/DIACARE.13.3.228 
57.  Nuutila P, Knuuti MJ, Maki M, et al. Gender and insulin sensitivity in the heart and in 
skeletal muscles: Studies using positron emission tomography. Diabetes. 
1995;44(1):31-36. doi:10.2337/diab.44.1.31 
58.  Borissova AM, Tankova T, Kirilov G, Koev D. Gender-dependent effect of ageing on 
peripheral insulin action. Int J Clin Pract. 2005;59(4):422-426. doi:10.1111/j.1368-
5031.2005.00209.x 
59.  Karakelides H, Irving BA, Short KR, O’Brien P, Sreekumaran Nair K. Age, obesity, 
and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. 
Diabetes. 2010;59(1):89-97. doi:10.2337/db09-0591 
60.  Høeg LD, Sjøberg KA, Jeppesen J, et al. Lipid-induced insulin resistance affects 
women less than men and is not accompanied by inflammation or impaired proximal 
 72 
insulin signaling. Diabetes. 2011;60(1):64-73. doi:10.2337/db10-0698 
61.  Gómez-Pérez Y, Amengual-Cladera E, Català-Niell A, et al. Gender Dimorphism in 
High-Fat-Diet-Induced Insulin Resistance in Skeletal Muscle of Aged Rats. Vol 22.; 
2008. doi:10.1159/000185538 
62.  Macotela Y, Boucher J, Tran TT, Kahn CR. Sex and depot differences in adipocyte 
insulin sensitivity and glucose. Diabetes. 2009;58(4):803-812. doi:10.2337/db08-1054 
63.  Jackson A, Stanforth P, Gagnon J, et al. The effect of sex, age and race on estimating 
percentage body fat from body mass index: The Heritage Family Study. Int J Obes. 
2002;26(6):789-796. doi:10.1038/sj.ijo.0802006 
64.  Uranga AP, Levine J, Jensen M. Isotope tracer measures of meal fatty acid 
metabolism: reproducibility and effects of the menstrual cycle. Am J Physiol Metab. 
2005;288(3):E547-E555. doi:10.1152/ajpendo.00340.2004 
65.  Carter SL, Rennie C, Tarnopolsky MA. Substrate utilization during endurance exercise 
in men and women after endurance training. Am J Physiol Metab. 2001;280(6):E898-
E907. doi:10.1152/ajpendo.2001.280.6.E898 
66.  McKenzie S, Phillips SM, Carter SL, Lowther S, Gibala MJ, Tarnopolsky M a. 
Endurance exercise training attenuates leucine oxidation and BCOAD activation during 
exercise in humans. Am J Physiol Endocrinol Metab. 2000;278(4):E580-E587. 
doi:10.1152/ajpendo.2000.278.4.E580 
67.  Devries MC, Hamadeh MJ, Phillips SM, Tarnopolsky MA. Menstrual cycle phase and 
sex influence muscle glycogen utilization and glucose turnover during moderate-
intensity endurance exercise. Am J Physiol Integr Comp Physiol. 2006;291(4):R1120-
R1128. doi:10.1152/ajpregu.00700.2005 
 73 
68.  Amiel SA, Maran A, Powrie JK, Umpleby AM, Macdonald IA. Gender differences in 
counterregulation to hypoglycaemia. Diabetologia. 1993;36(5):460-464. 
doi:10.1007/BF00402284 
69.  Diamond MP, Jones T, Caprio S, et al. Gender influences counterregulatory hormone 
responses to hypoglycemia. Metabolism. 1993;42(12):1568-1572. 
http://www.ncbi.nlm.nih.gov/pubmed/8246771. Accessed October 16, 2018. 
70.  Davis SN, Cherrington AD, Goldstein RE, Jacobs J, Price L. Effects of insulin on the 
counterregulatory response to equivalent hypoglycemia in normal females. Am J 
Physiol Metab. 1993;265(5):E680-E689. doi:10.1152/ajpendo.1993.265.5.E680 
71.  Davis SN, Shavers C, Costa F. Differential gender responses to hypoglycemia are due 
to alterations in CNS drive and not glycemic thresholds. Am J Physiol Metab. 
2000;279(5):E1054-E1063. doi:10.1152/ajpendo.2000.279.5.E1054 
72.  Fanelli C, Pampanelli S, Epifano L, et al. Relative roles of insulin and hypoglycaemia 
on induction of neuroendocrine responses to, symptoms of, and deterioration of 
cognitive function in hypoglycaemia in male and female humans. Diabetologia. 
1994;37(8):797-807. http://www.ncbi.nlm.nih.gov/pubmed/7988782. Accessed 
November 8, 2018. 
73.  Davis SN, Galassetti P, Wasserman DH, Tate D. Effects of gender on neuroendocrine 
and metabolic counterregulatory responses to exercise in normal man. J Clin 
Endocrinol Metab. 2000;85(1):224-230. doi:10.1210/jc.85.1.224 
74.  Ikegami H, Noso S, Babaya N, Kawabata Y. Genetics and pathogenesis of type 1 
diabetes: prospects for prevention and intervention. J Diabetes Investig. 2011;2(6):415-
420. doi:10.1111/j.2040-1124.2011.00176.x 
 74 
75.  Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes: what’s next? 
Diabetes. 2010;59(7):1561-1571. doi:10.2337/db10-0076 
76.  Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ Haplotypes and Genotypes and 
Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families. 
Diabetes. 2008;57(4):1084-1092. doi:10.2337/db07-1331 
77.  Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for Islet 
Autoimmunity among Monozygotic Twins. N Engl J Med. 2008;359(26):2849-2850. 
doi:10.1056/NEJMc0805398 
78.  Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb 
Perspect Biol. 2012;4(6):1-15. doi:10.1101/cshperspect.a007690 
79.  American Diabetes Association. Glycemic Targets: Standards of Medical Care in 
Diabetes-2018. Diabetes Care. 2018;41(1):S55-S64. doi:10.2337/dc18-S006 
80.  Triplitt CL. Understanding the kidneys’ role in blood glucose regulation. Am J Manag 
Care. 2012;18(1 Suppl):S11-6. http://www.ncbi.nlm.nih.gov/pubmed/22559853. 
Accessed December 10, 2017. 
81.  Lee Y, Wang M-Y, Du XQ, Charron MJ, Unger RH. Glucagon Receptor Knockout 
Prevents Insulin-Deficient Type 1 Diabetes in Mice. Diabetes. 2011;60(2):391-397. 
doi:10.2337/db10-0426 
82.  Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on 
glucose tolerance in humans. Am J Physiol Metab. 1999;277(2):E283-E290. 
doi:10.1152/ajpendo.1999.277.2.E283 
83.  Gerich JE, Lorenzi M, Bier DM, et al. Prevention of Human Diabetic Ketoacidosis by 
Somatostatin. N Engl J Med. 1975;292(19):985-989. 
 75 
doi:10.1056/NEJM197505082921901 
84.  Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to 
postprandial hyperglycaemia in IDDM. Diabetologia. 1995;38(3):337-343. 
http://www.ncbi.nlm.nih.gov/pubmed/7758881. Accessed November 22, 2018. 
85.  Mogensen CE. Maximum Tubular Reabsorption Capacity for Glucose and Renal 
Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic 
Subjects. Scand J Clin Lab Invest. 1971;28(1):101-109. 
doi:10.3109/00365517109090668 
86.  Johansen K, Svendsen PA, Lørup B. Variations in renal threshold for glucose in Type 1 
(insulin-dependent) diabetes mellitus. Diabetologia. 1984;26(3):180-182. 
http://www.ncbi.nlm.nih.gov/pubmed/6714538. Accessed October 29, 2018. 
87.  Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose 
transporters in human renal proximal tubular cells isolated from the urine of patients 
with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-3434. 
http://www.ncbi.nlm.nih.gov/pubmed/16306358. Accessed October 29, 2018. 
88.  Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of Suppression of 
Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes 
Mellitus 1. J Clin Endocrinol Metab. 2000;85(11):4053-4059. 
doi:10.1210/jcem.85.11.6993 
89.  Pörksen S, Nielsen LB, Kaas A, et al. Meal-Stimulated Glucagon Release Is 
Associated with Postprandial Blood Glucose Level and Does Not Interfere with 
Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes. J 
Clin Endocrinol Metab. 2007;92(8):2910-2916. doi:10.1210/jc.2007-0244 
 76 
90.  Barrett EJ, DeFronzo RA, Bevilacqua S, Ferrannini E. Insulin resistance in diabetic 
ketoacidosis. Diabetes. 1982;31(10):923-928. doi:10.2337/diab.31.10.923 
91.  Yale J-F, Paty B, Senior PA. 2018 Clinical Practice Guidelines Hypoglycemia 
Diabetes Canada Clinical Practice Guidelines Expert Committee. Can J Diabetes. 
2018. doi:10.1016/j.jcjd.2017.10.010 
92.  Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and Management of Adult 
Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. J Clin 
Endocrinol Metab. 2009;94(3):709-728. doi:10.1210/jc.2008-1410 
93.  Siafarikas A, Johnston RJ, Bulsara MK, O’Leary P, Jones TW, Davis EA. Early loss of 
the glucagon response to hypoglycemia in adolescents with type 1 diabetes. Diabetes 
Care. 2012;35(8):1757-1762. doi:10.2337/dc11-2010 
94.  Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and 
hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. 
Endocrinol Metab Clin North Am. 2013;42(1):15-38. doi:10.1016/j.ecl.2012.11.005 
95.  Amiel SA, Sherwin RS, Simonson DC, Tamborlane W V. Effect of intensive insulin 
therapy on glycemic thresholds for counterregulatory hormone release. Diabetes. 
1988;37(7):901-907. http://www.ncbi.nlm.nih.gov/pubmed/3290007. Accessed 
October 31, 2018. 
96.  McMahon SK, Ferreira LD, Ratnam N, et al. Glucose Requirements to Maintain 
Euglycemia after Moderate-Intensity Afternoon Exercise in Adolescents with Type 1 
Diabetes Are Increased in a Biphasic Manner. J Clin Endocrinol Metab. 
2007;92(3):963-968. doi:10.1210/jc.2006-2263 
97.  Cheng Y, Shen J, Ren W, et al. Mild hyperglycemia triggered islet function recovery in 
 77 
streptozotocin-induced insulin-deficient diabetic rats. J Diabetes Investig. 
2017;8(1):44-55. doi:10.1111/jdi.12540 
98.  Grossman EJ, Lee DD, Tao J, et al. Glycemic Control Promotes Pancreatic Beta-Cell 
Regeneration in Streptozotocin-Induced Diabetic Mice. Maedler K, ed. PLoS One. 
2010;5(1):e8749. doi:10.1371/journal.pone.0008749 
99.  Petersen C. Analyse des Phloridzins. Ann der Pharm. 1835;15(2):178-178. 
doi:10.1002/jlac.18350150210 
100.  von Mering J. Ueber kunstlichen Diabetes. Cent Med Wiss. 1886;xxii(531). 
101.  Leveen HH, Leveen RF, Leveen EG. Treatment of cancer with phlorizin and its 
derivatives. 1989. https://www.google.com/patents/US4840939. 
102.  Stiles P, Lusk G. On the action on phlorizin. Am J Physiol. 1903;10:61-79. 
103.  Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of 
hyperglycemia with phlorizin normalizes tissues sensitivity to insulin in diabetic rats. J 
Clin Invest. 1987;79(5):1510-1515. doi:10.1172/JCI112981 
104.  Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport 
explains renal glucose reabsorption during genetic and pharmacological SGLT2 
inhibition in euglycemia. AJP Ren Physiol. 2014;306(2):F188-F193. 
doi:10.1152/ajprenal.00518.2013 
105.  Vallon V, Platt KA, Cunard R, et al. SGLT2 Mediates Glucose Reabsorption in the 
Early Proximal Tubule. J Am Soc Nephrol. 2011;22(1):104-112. 
doi:10.1681/ASN.2010030246 
106.  Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and 
pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in 
 78 
patients with type 2 diabetes. Diabetes, Obes Metab. 2013;15(7):613-621. 
doi:10.1111/dom.12073 
107.  Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 
inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 
2009;85(5):520-526. doi:10.1038/clpt.2008.251 
108.  Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-
transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. 
Diabetes, Obes Metab. 2014;16(5):457-466. doi:10.1111/dom.12244 
109.  Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group. 
Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on 
Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind 
Clinical Trial. Diabetes Care. 2015;38(3):365-372. doi:10.2337/dc14-0666 
110.  Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight 
Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin 
Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately 
Controlled Type 2 Diabetes. Diabetes Care. 2014;37(7):1815-1823. doi:10.2337/dc13-
3055 
111.  Cefalu WT, Leiter LA, de Bruin TWA, Gause-Nilsson I, Sugg J, Parikh SJ. 
Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk 
Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, 
Placebo-Controlled Study With a 28-Week Extension. Diabetes Care. 
2015;38(7):1218-1227. doi:10.2337/dc14-0315 
112.  Cefalu WT, Stenlöf K, Leiter LA, et al. Effects of canagliflozin on body weight and 
 79 
relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. 
Diabetologia. 2015;58(6):1183-1187. doi:10.1007/s00125-015-3547-2 
113.  Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and 
Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. 
doi:10.1056/NEJMoa1504720 
114.  Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal 
Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. 
doi:10.1056/NEJMoa1611925 
115.  Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and Safety of Canagliflozin, an 
Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin 
Therapy in Patients With Type 2 Diabetes. Diabetes Care. 2015;38(3):403-411. 
doi:10.2337/dc14-1237 
116.  Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal 
insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week 
randomized, double-blind, placebo-controlled trial. Diabetes, Obes Metab. 
2015;17(10):936-948. doi:10.1111/dom.12503 
117.  Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin 
monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet 
and exercise alone. Diabetes, Obes Metab. 2017;19(5):721-728. 
doi:10.1111/dom.12888 
118.  Takeishi S, Tsuboi H, Takekoshi S. Comparison of tofogliflozin 20 mg and 
ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous 
glucose monitoring (CGM): A randomized crossover study. Endocr J. 
 80 
2017;64(10):995-1005. doi:10.1507/endocrj.EJ17-0206 
119.  Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, 
detectable, and preventable safety concern with sglt2 inhibitors. Diabetes Care. 
2015;38(9):1638-1642. doi:10.2337/dc15-1380 
120.  Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of 
canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in 
patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258-2265. 
doi:10.2337/dc15-1730 
121.  Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients 
with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a 
multicentre, double-blind, phase 3, randomised controlled trial. lancet Diabetes 
Endocrinol. 2017;5(11):864-876. doi:10.1016/S2213-8587(17)30308-X 
122.  Mathieu C, Dandona P, Gillard P, et al. Efficacy and Safety of Dapagliflozin in 
Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-
Week Results From a Randomized Controlled Trial. Diabetes Care. 2018;41(9):1938-
1946. doi:10.2337/dc18-0623 
123.  Garg SK, Henry RR, Banks P, et al. Effects of Sotagliflozin Added to Insulin in 
Patients with Type 1 Diabetes. N Engl J Med. 2017:NEJMoa1708337. 
doi:10.1056/NEJMoa1708337 
124.  Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of 
sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. 
Circulation. 2014;129(5):587-597. doi:10.1161/CIRCULATIONAHA.113.005081 
125.  Tamez HE, Tamez AL, Garza LA, Hernandez MI, Polanco AC. Dapagliflozin as an 
 81 
adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J 
Diabetes Metab Disord. 2015;14(1):78. doi:10.1186/s40200-015-0210-x 
126.  Cohen J, Berglund F, Lotspeich W. Renal tubular reabsorption of acetoacetate, 
inorganic sulfate and inorganic phosphate in the dog as affected by glucose and 
phlorizin. Am J Physiol. 1956;184(1):91-96. doi:21200294 
127.  Millar P, Pathak N, Parthsarathy V, et al. Metabolic and neuroprotective effects of 
dapagliflozin and liraglutide in diabetic mice. J Endocrinol. 2017;234(3):255-267. 
doi:10.1530/JOE-17-0263 
128.  Neschen S, Scheerer M, Seelig A, et al. Metformin Supports the Antidiabetic Effect of 
a Sodium Glucose Cotransporter 2 Inhibitor by Suppressing Endogenous Glucose 
Production in Diabetic Mice. Diabetes. 2015;64(1):284-290. doi:10.2337/db14-0393 
129.  Petrie JR. SGLT2 inhibitors in type 1 diabetes: knocked down, but up again? Lancet 
Diabetes Endocrinol. 2017;5(11):841-843. doi:10.1016/S2213-8587(17)30315-7 
130.  Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et 
al. The effect of intensive treatment of diabetes on the development and progression of 
long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 
1993;329(14):977-986. doi:10.1056/NEJM199309303291401 
131.  Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 
2010;39(3):641-654. doi:10.1016/j.ecl.2010.05.003 
132.  Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year 
natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of 
Diabetes Complications Study experience. Diabetes. 2006;55(5):1463-1469. 
doi:10.2337/DB05-1423 
 82 
133.  Brazeau A-S, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to physical activity 
among patients with type 1 diabetes. Diabetes Care. 2008;31(11):2108-2109. 
doi:10.2337/dc08-0720 
134.  Tat V, Forest CP. The role of SGLT2 inhibitors in managing type 2 diabetes. J Am 
Acad Physician Assist. 2018;31(6):35-40. doi:10.1097/01.JAA.0000533660.86287.04 
135.  Vallon V. The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes 
Mellitus. Annu Rev Med. 2015;66(1):255-270. doi:10.1146/annurev-med-051013-
110046 
136.  Chen L, Mao Y, Sharp D, et al. Pharmacokinetics, Biotransformation, Distribution and 
Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) Inhibitor, in 
Mice, Rats, and Dogs. J Pharm Drug Dev. 2015;3(3):1. doi:10.15744/2348-9782.3.302 
137.  Russell JC, Epling WF, Pierce D, Amy RM, Boer DP. Induction of voluntary 
prolonged running by rats. J Appl Physiol (Bethesda, Md 1985). 1987;63(6):2549-
2553. doi:10.1152/jappl.1987.63.6.2549 
138.  Ishihara H, Maechler P, Gjinovci A, Herrera P-L, Wollheim CB. Islet β-cell secretion 
determines glucagon release from neighbouring α-cells. Nat Cell Biol. 2003;5(4):330-
335. doi:10.1038/ncb951 
139.  Abdul-Ghani M, DeFronzo RA. Fasting Hyperglycemia Impairs Glucose- But Not 
Insulin-Mediated Suppression of Glucagon Secretion. J Clin Endocrinol Metab. 
2007;92(5):1778-1784. doi:10.1210/jc.2006-1515 
140.  Leclair E, Liggins RT, Peckett AJ, et al. Glucagon responses to exercise-induced 
hypoglycaemia are improved by somatostatin receptor type 2 antagonism in a rat 
model of diabetes. Diabetologia. 2016;59(8):1724-1731. doi:10.1007/s00125-016-
 83 
3953-0 
141.  Jones LC, Bellingham WP, Ward LC. Sex differences in voluntary locomotor activity 
of food-restricted and ad libitum-fed rats. Implications for the maintenance of a body 
weight set-point. Comp Biochem Physiol A Comp Physiol. 1990;96(2):287-290. 
http://www.ncbi.nlm.nih.gov/pubmed/1976470. Accessed November 8, 2018. 
142.  Galassetti P, Tate D, Neill RA, Morrey S, Davis SN. Effect of Gender on 
Counterregulatory Responses to Euglycemic Exercise in Type 1 Diabetes. J Clin 
Endocrinol Metab. 2002;87(11):5144-5150. doi:10.1210/jc.2002-020757 
143.  Davis SN, Fowler S, Costa F. Hypoglycemic counterregulatory responses differ 
between men and women with type 1 diabetes. Diabetes. 2000;49(1):65-72. 
http://www.ncbi.nlm.nih.gov/pubmed/10615951. Accessed November 9, 2018. 
144.  Wiik A, Gustafsson T, Esbjornsson M, et al. Expression of oestrogen receptor alpha 
and beta is higher in skeletal muscle of highly endurance-trained than of moderately 
active men. Acta Physiol Scand. 2005;184(2):105-112. doi:10.1111/j.1365-
201X.2005.01433.x 
145.  Gorres BK, Bomhoff GL, Morris JK, Geiger PC. In vivo stimulation of oestrogen 
receptor α increases insulin-stimulated skeletal muscle glucose uptake. J Physiol. 
2011;589(8):2041-2054. doi:10.1113/jphysiol.2010.199018 
146.  Yardley JE, Brockman NK, Bracken RM. Could Age, Sex and Physical Fitness Affect 
Blood Glucose Responses to Exercise in Type 1 Diabetes? Front Endocrinol 
(Lausanne). 2018;9:674. doi:10.3389/fendo.2018.00674 
147.  Brockman NK, Yardley JE. Sex-related differences in fuel utilization and hormonal 
response to exercise: implications for individuals with type 1 diabetes. Appl Physiol 
 84 
Nutr Metab. 2018;43(6):541-552. doi:10.1139/apnm-2017-0559 
148.  Horton TJ, Dow S, Armstrong M, Donahoo WT. Greater systemic lipolysis in women 
compared with men during moderate-dose infusion of epinephrine and/or 
norepinephrine. J Appl Physiol. 2009;107(1):200-210. 
doi:10.1152/japplphysiol.90812.2008 
149.  Henderson GC, Fattor JA, Horning MA, et al. Glucoregulation is more precise in 
women than in men during postexercise recovery. Am J Clin Nutr. 2008;87(6):1686-
1694. doi:10.1093/ajcn/87.6.1686 
 
